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Executive Summary 
Objectives 
To synthesize the best available evidence on the safety and effectiveness of 
pharmacist prescribing on patient outcomes in patients who present to hospital. 
Background 
Pharmacist prescribing is legal in many countries. Different models of prescribing 
include dependent, collaborative and independent. Existing reviews of pharmacist 
prescribing focus on studies in the community setting, or both community and hospital 
settings. Other reviews focus on descriptions of current practice or perspectives of 
clinicians and patients on the practice of pharmacist prescribing. A systematic review 
on the effects of pharmacist prescribing on patient outcomes in the hospital has not 
been previously undertaken and is important as this practice can help ease the 
burden on the healthcare system.  
Inclusion criteria 
Studies with controlled experimental designs comparing pharmacist prescribing to 
medical prescribing in the hospital setting were included in the review. Primary 
outcomes of interest included clinical outcomes such as therapeutic failure or benefit, 
adverse effects and morbidity or mortality. Secondary outcomes included error rates 
in prescriptions, medication omissions on the medication chart, time or proportion of 
International Normalized Ratios in therapeutic range, time to reach therapeutic range 
and patient satisfaction.  
Methods  
A comprehensive three-step search strategy was utilized. The search was conducted 
in January 2017 in eight major databases from database inception.  Only studies in 
English were included. The recommended Joanna Briggs Institute approach to critical 
appraisal, study selection and data extraction was used. Narrative synthesis was 








The fifteen included studies related to dependent and collaborative prescribing 
models. In four studies that measured clinical outcomes, there was no difference in 
blood pressure management between pharmacists and doctors while patients of 
pharmacist prescribers had better cholesterol levels (mean difference in low density 
lipoprotein of 0.4 mmol/L in one study and 1.1 mmol/L in another; mean difference in 
total cholesterol of 1.0 mmol/L) and blood sugar levels (mean difference of fasting 
blood sugar levels of 15 mg/dL, mean difference of glycosylated hemoglobin of 2.6 
%). In two studies, pharmacists were better at adhering to warfarin dosing 
nomograms than doctors (average of 100% versus 62% compliance). In six studies, 
when prescribing warfarin according to dosing nomograms, equivalent numbers or 
more patients were maintained in therapeutic range by pharmacist prescribers 
compared to doctors. The incidence of adverse effects related to anticoagulant 
prescribing was similar across arms but all six studies were underpowered to detect 
this outcome. Three studies found that pharmacist prescribers made less prescribing 
errors (20 to 25 times less errors) and omissions (three to 116 times less omissions) 
than doctors when prescribing patients’ usual medications on admission to hospital or 
in the pre-operative setting. Two studies reported that patients were as satisfied with 
the services provided by pharmacist prescribers as with doctors.      
Conclusions 
This review provides low to moderate evidence that pharmacists can prescribe to the 
same standards as doctors. Compared to doctors, pharmacists are better at adhering 
to dosing guidelines when prescribing by protocol and make significantly less 
prescribing errors when charting patients’ usual medications on admission to hospital. 
Keywords 
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Summary of Findings 
The effects of Pharmacist Presc ribing on Patient Outcomes in the Hospital 
Setting: A Systematic Review 
P: All patients in a hospital setting (in hospital, pre-admission clinic or outpatients) 
I: Pharmacist prescribing 
C: Usual care by hospital doctors  










follow up: range 6 
to 29 months 
Pharmacists were just as effective 
as doctors in prescribing 
medications for blood pressure 
control.  
Mean change in SBP from baseline 
was +2 mmHg and -2 mmHg in the 
intervention and control arm 
respectively in one study (excluding 












control follow up: 
range 12 to 29 
months 
Pharmacists were just as effective 
as doctors in prescribing 
medications for blood sugar control.  
Two studies reported a reduction in 
mean change from baseline in the 
intervention arm compared to the 
control arm: -8 mg/dL versus +7 
mg/dL (fasting blood sugar levels) in 
one study and -1.8 % versus -0.8 % 
(glycosylated haemoglobin) in 
another study.    
793 









follow up: range 6 
to 12 months 
Pharmacists were just as effective 
as doctors in prescribing 
medications for cholesterol control.  
Two studies reported a reduction in 
mean change from baseline in the 
intervention arm compared to the 
control arm for LDL: -0.7 mmol/L 
versus -0.3 mmol/L mmol/L in one 
study and -1.3 mmol/L versus -0.2 
mmol/L in another. One study 
reported a reduction in mean 
change from baseline in the 
intervention arm compared to the 
control arm for TC: -1.1 mmol/L 
versus  -0.1 mmol/L.    
178 
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omitted from chart 
Pharmacist prescribing of patients’ 
usual medications on admission to 
hospital or in the preadmission clinic 
reduced prescribing error rates and 
the omission of medications from 
medication charts. 
Average number of prescribing 
errors was 4.5 (range 2 – 7) in the 
intervention arm and 113.5 (range 
51 – 176) in the control arm (two 
studies). Average number of 
medication omissions was 11.5 
(range 11 – 12) in the intervention 
arm and 890 (range 383 – 1397) in 
the control arm (two studies).  
1486 












Pharmacists were just as effective 
as doctors in prescribing 
anticoagulants according to dosing 
nomograms, with little or no 
difference in adverse effect events. 
The number of events between 
arms were similar in all studies but 
these studies were underpowered 
and a meaningful conclusion cannot 
be drawn.  
901 










Pharmacist prescribing of warfarin 
improved adherence to dosing 
nomograms. 
On average, pharmacist prescribers 
complied with dosing nomograms 
100% of the time compared to 
doctors who complied 62% (range 
46% – 73%) of the time.   
117 









Pharmacist prescribing of warfarin 
improved patient-time spent in 
therapeutic range.  
Patient time, percentage of patients 
or INR in therapeutic range ranged 
from 57% – 78% in the intervention 
arm compared to 18% – 79% in the 
control arm. 
958 
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GRADE Working Group grades of evidence  
High quality:  We are very confident that the true effect lies close to that of the estimate of the 
effect 
Moderate quality:  We are moderately confident in the effect estimate: The true effect is likely 
to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low quality:  Our confidence in the effect estimate is limited: The true effect may be 
substantially different from the estimate of the effect 
Very low quality:  We have very little confidence in the effect estimate: The true effect is likely 
to be substantially different from the estimate of effect 
Explanations 
a. No allocation concealment or unable to be established  
b. Unable to establish if outcome assessors blinded  
c. Participants or those delivering treatment not blinded  
d. Used surrogate outcomes but the surrogate marker is well established as a marker for 
morbidity or mortality; evidence level not downgraded  
e. Small number of participants  
f. Includes quasi experimental trials and may be affected by allocation bias  
g. Small number of events  
Legend: INR=International Normalized Ratio, LDL=Low Density Lipoprotein, 
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CHAPTER 1: INTRODUCTION 
1.1 Evidence based healthcare and Systematic Review s 
In an ideal world, clinicians would have access to standardized guidelines for any 
treatable or modifiable disease state when providing healthcare to patients. In reality, 
practice is guided mainly by limited and often conflicting evidence, combined with a 
clinician’s own clinical experience and opinions. In order to ensure that the provision 
of healthcare was supported by sound evidence, the concept of evidence based 
medicine was conceived. Evidence based medicine is the provision of medical care 
for patients based on the integration of the best available evidence obtained through 
systematic review of scientific evidence and the individual clinical expertise of 
practitioners.1,2 The importance of well-designed systematic reviews cannot be over-
emphasized, as there are a multitude of published studies available in the literature, 
without taking into account gray literature. In 2014, there were estimated to be 28,100 
active scholarly peer-reviewed English-language journals, publishing close to 2.5 
million articles a year in total.3 Clinicians cannot afford the time to sift through the 
incredible amount of information available in order to deliver evidence-based practice. 
Systematic reviews can streamline the information gathering process, providing 
clinicians with a summary of the current evidence in addition to recommendations for 
practice based on the synthesized findings.  
Liberati et al. has described systematic reviews in the following statement: “A 
systematic review attempts to collate all empirical evidence that fits pre-specified 
eligibility criteria to answer a specific research question. It uses explicit, systematic 
methods that are selected with a view to minimizing bias, thus providing reliable 
findings from which conclusions can be drawn and decisions made”.4(p.2) Traditionally, 
systematic reviews, with or without meta-analyses, are considered to provide the 
highest level of evidence. A number of international collaborations including the 
Joanna Briggs Institute and the Cochrane Collaboration have published 
methodologies on conducting systematic reviews.5,6,7,8,9 The recommended 
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share key characteristics which aim at improving the quality of these reviews through 
increased transparency of the reporting process. These key characteristics include: 
• A clearly defined clinical question; 
• An explicit methodology which can be replicated; 
• A systematic search in all pertinent databases; (including repositories for gray 
literature, in an attempt to identify relevant studies which meet the inclusion 
criteria; 
• A critical appraisal of the study methodology; 
• Critical assessment of the outcomes of the studies included in the review; 
• Assessment of the studies to rank the quality of the evidence (e.g. with the use 
of Grading of Recommendations Assessment, Development and Evaluation or 
GRADE);9 and 
• Synthesis and presentation of the findings and the included studies.  
Systematic reviews help clinicians analyze large bodies of evidence and inform 
clinical decision making, and can also assist in establishing clinical policies at a local, 
national or international level, avoid studies being conducted unnecessarily where 
sufficient evidence is available, or even provide direction on future research that 
should be considered. Ultimately, systematic reviews on healthcare interventions aim 
to provide patients with optimal clinical outcomes and a better quality of life.  
 
1.2 Medical Prescribing  
For conditions that can be medically managed, diagnosis is often followed by 
prescribing of medications to treat the condition or alleviate symptoms associated 
with the condition. Prescribing has been defined as “an iterative process involving the 
steps of information gathering, clinical decision making, communication and 
evaluation, which results in the initiation, continuation or cessation of a 
medicine”.10(p.5) In other words, the act of prescription writing is not an independent 
task. It also involves the skills of interpreting relevant test results, diagnosis and 
initiation of medication therapy if appropriate following discussion with the patient. 
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adverse effects and ongoing need for the patient. Where appropriate, the medication 
dose should be modified or the medication ceased where its clinical need no longer 
exists. These elements of prescribing have been listed and described in detail by the 
World Health Organization in a six step approach: 
• “STEP 1: Define the patient’s problem 
• STEP 2: Specify the therapeutic objective 
• STEP 3: Verify the suitability of your P-druga 
• STEP 4: Write a prescription 
• STEP 5: Give information, instructions and warnings 
• STEP 6: Monitor (and stop?) the treatment”.11(p.i) 
Although legislative requirements vary from country to country, medication prescribing 
is always limited to selected registered health practitioners. Traditionally, the act of 
prescribing has been associated with doctors, but this role has expanded to include 
other health professionals in recent years. 
 
1.3 Non-medical Prescribing 
Non-medical prescribing is the extension of prescribing rights to other specified 
professions, including nurses, pharmacists, optometrists and podiatrists. It was 
originally introduced to allow a more flexible system for the prescribing, supply and 
administration of medications in order to help improve patients’ access to medications 
and ease the workload burden on general practitioners.12,13 Non-medical prescribing 
was first introduced for nurse practitioners in the United States of America (USA) in 
1969 and in the United Kingdom (UK) in 1986.14,15 In the last two decades, legislation 
changes have also occurred in various countries around the world to allow for non-
medical prescribing.10,14,16  
                                            
a P-drug refers to a prescriber’s personal selection of drugs which are prescribed in preference to other 
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1.3.1 Pharmacist Prescribing 
Pharmacists have been prescribing medications to some extent even before 
legislative changes occurred to formalize this process. In the UK, medications 
available to the general public are broadly divided into three classes – prescription 
only medicines, pharmacy medicines and medicines on the general sale list.17 
Prescription only medicines, as the name suggests, are only available when a 
prescription is written by a health practitioner authorized to prescribe. Pharmacy 
medicines are available for purchase without a prescription at a pharmacy or under 
the supervision of a pharmacist and medicines on the general sale list can be 
purchased from outlets such as supermarkets in addition to pharmacies. This system 
of medication classification is similar in Australia, where medications are listed in 
schedules that outline requirements associated with the medications in each 
schedule. Medications listed in Schedule 4 (S4) or Schedule 8 (S8) medications can 
only be obtained with a prescription. Schedule 3 (S3) medications are available when 
provided by a pharmacist at any registered pharmacy, Schedule 2 (S2) medications 
are available at any registered pharmacy, and unscheduled medications are available 
from any outlet.18 
When pharmacy only medicines (UK) or S3 medicines (Australia) are purchased at a 
pharmacy, a pharmacist must be involved in the sale of the product. There is an 
expectation that the pharmacist will diagnose, make a clinical decision, prescribe the 
medication and provide medication counselling to the patient, although this process is 
informal. For example, under Australian regulations, a pharmacist does not require a 
prescription to dispense the emergency contraceptive pill, corticosteroid cream 
(hydrocortisone) for skin irritations, oral antifungal (fluconazole) for vaginal thrush or 
antibacterial eye drops (chloramphenicol) for conjunctivitis. However, in order to 
ensure the medication is used appropriately and safely by the patient, the pharmacist 
must, as part of their duty of care, diagnose the patient correctly, check there are no 
contraindications to the use of the medication for the patient and provide the patient 
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Pharmacist prescribing is currently legal in Canada, New Zealand, the UK and the 
USA.13,19 In the UK, limited prescribing rights for pharmacists were introduced in 2003 
followed by independent prescribing in 2006.20 In addition to the benefits described 
above, extending the scope of practice for pharmacists through prescribing utilizes 
pharmacists’ expertise on medications, particularly their understanding of 
pharmacology and pharmacokinetics.  
Different models of pharmacist prescribing have been described in the 
literature.12,16,19 They include independent, dependent and collaborative prescribing. 
For the purposes of this review, the types of pharmacist prescribing have been 
defined as independent, collaborative and dependent.  
In independent prescribing, pharmacists have the greatest autonomy in prescribing 
medications and are responsible for the assessment, diagnosis and clinical 
management of patients.  
In collaborative prescribing, there is a cooperative practice relationship between the 
pharmacist and doctor. The doctor diagnoses and makes initial treatment decisions 
for the patient while the pharmacist selects, monitors, modifies, continues or 
discontinues the treatment as appropriate.  
Dependent prescribing places more restrictions on the non-medical prescriber by 
limiting medication prescription according to protocols or formularies. The different 
types of dependent prescribing include prescribing by protocol, prescribing by 
formulary, repeat prescribing and supplementary prescribing. In prescribing by 
protocol a written guideline (protocol) describes in explicit detail the activities that may 
be performed by the non-medical practitioner. The protocol includes a limited list of 
the diseases and medication classes which the practitioner may prescribe. The 
protocol may also list medications in preferential order, along with suggested doses 
and provide recommendations on when dose modification should be considered. 
Detailed protocols also contain additional clinical information such as laboratory tests 
(e.g. renal function) or diagnostic tests (e.g. blood pressure monitoring) that should be 
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prescribe from a predefined list of medications for specific medical conditions.  
Medications not on the list may not be prescribed. Repeat prescribing is a medication-
refill service where pharmacists in clinics prescribe for patients who require continuing 
prescriptions prior to their next available appointment with their doctor. In 
supplementary prescribing a voluntary partnership between the doctor and 
pharmacist exists, where the doctor undertakes the initial assessment and the 
pharmacist prescribes in accordance with the doctor’s documented care plan. The 
care plan clearly outlines the therapeutic options agreed upon by the doctor and 
patient. 










Figure 1: Relative Autonomy of Pharmacist Prescribi ng Models 
 
1.4 Systematic Reviews on Pharmacist Prescribing 
Systematic reviews on non-medical prescribing, specifically nurse prescribing, are 
available in the literature.21,22 Other reviews of non-medical prescribing are also 
available but do not focus exclusively on pharmacist prescribing in the hospital 
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prescribing by nurses and allied health professionals, but was limited to the primary 
care setting.14 This review identified the lack of studies of non-medical prescribing in 
the primary care setting which was a barrier to evidence based policy making. A more 
recent review published in 2016 reported on non-medical prescribing in both primary 
and secondary care settings, but presented combined results for all allied health 
professionals, including pharmacist prescribers.23 This review concluded that non-
medical prescribers were as effective as usual care medical prescribers and could 
deliver comparable clinical outcomes and health-related quality of life, as well as 
intermediary outcomes related to medication adherence and patient satisfaction. 
In 2004, a review focusing on pharmacist prescribing was published, and included 
prescribing in both the community and hospital setting.24 This review identified only 
four studies with an experimental design and concluded that additional research was 
needed to establish the validity of pharmacist prescribing. In a review which evaluated 
the impact of pharmacists in the area of mental health, some studies involving 
pharmacist prescribing were included but these studies were not the main focus of 
the review.25 Other published reviews which have included pharmacist prescribing 
mainly relate to descriptions of the practice (including existing policies and 
procedures) in a specific country or region, barriers to successful implementation, or 
the perspectives of pharmacist prescribers, other healthcare professionals or patients 
on pharmacist prescribing.13,19,26 A systematic review on the effects of pharmacist 
prescribing on patient outcomes in the hospital setting is therefore warranted as an 
expanded scope of practice for pharmacists can ease the burden on the healthcare 
system. The current review was conducted according to an a priori published 
protocol.27 
1.5 Identifying Outcomes of interest 
Outcomes of interest in this review were related to patient outcomes in the hospital 
setting, where patients were either inpatients or outpatients. Outcomes of interest 
were specifically chosen to be able to reflect the safety and effectiveness of 
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1.5.1 Therapeutic failure or benefit 
Therapeutic failure or benefit was chosen as one of the primary outcomes of this 
review as efficacy of drugs undergoing clinical trials are usually assessed based on 
these clinically meaningful endpoints.28 Blood pressure control or diabetes control are 
considered surrogate endpoints as they are used as a marker for a more clinically 
meaningful outcome, which in this case would be the reduction in the incidence of 
morbidity and mortality related to cardiovascular disease. Therapeutic failure or 
benefit was used as a surrogate endpoint in measuring the ability of the prescriber 
(doctor or pharmacist) to select medications, initiate medications and titrate doses 
appropriately.   
1.5.2 Adverse events 
Adverse events (including incidence of morbidity and mortality) were also considered 
a primary outcome in this review as they can provide an indication of whether certain 
prescriber groups may be over-titrating medication doses, e.g. excessively high doses 
of warfarin can result in bleeding events. 
1.5.3 Prescribing errors 
Prescribing errors were chosen as a secondary outcome to determine if, from a 
patient safety point of view, pharmacists could prescribe just as safely as doctors. 
Prescribing errors are well described in the literature and have been defined by Dean 
et al. in the following manner: “A clinically meaningful prescribing error occurs when, 
as a result of a prescribing decision or prescription writing process, there is an 
unintentional significant (1) reduction in the probability of treatment being timely and 
effective or (2) increase in the risk of harm when compared with generally accepted 
practice”.29(p.235)  
Prescribing errors can broadly be divided into clinical errors and communication 
errors. Clinical errors, which include errors in drug selection, dose, route, frequency, 
significant drug interactions or omissions of prescribing, are the focus of this review. 
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discussed in detail in this review as the decision on whether these prescriptions 
constitute errors are more subjective than those of clinical errors.   
Prescribing errors in hospital inpatients are common with the reported rates varying 
depending on the study design and the definition used to describe a prescribing error. 
A systematic review published in 2009 found that 7% of medication orders, 2% of 
patient days and 50% of hospital admissions are affected by errors related to 
prescribing activities.30 Severity of errors should also be taken into account when 
considering prescribing errors as this can aid with assessment of their clinical 
significance. There are a multitude of severity assessment tools described in the 
literature, with different tools used in different studies which makes comparison 
across studies difficult.31 The National Coordinating Council for Medication Error 
Reporting and Prevention considers all medication errors, including prescribing 
errors, to be preventable.32 Strategies to reduce medication errors are important as 
these errors may lead to increased mortality rates, increased length of stay and 
increased medical costs related to the care of the patient.33 Junior doctors have been 
found to be more likely to make prescribing errors due to their inexperience, and other 
factors which increase the likelihood of prescribing errors including high workload, 
lack of skills, performance of tasks that are not part of normal duties or looking after 
another clinician’s patient.34  
1.5.4 Patient satisfaction 
Patient satisfaction surveys have been used as an approach to quality improvement 
in healthcare settings. They are considered an important quality outcome indicator in 
measuring the success of the service delivery system although not extensively used 
for developing improvement initiatives.35 Patient satisfaction was included as a 
secondary outcome measure in this review to determine if pharmacist prescribers 
would be able to meet patient expectations to the same level as doctors. 
1.6 Objectives  
The objective of this review was to determine the effects of pharmacist prescribing in 
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More specifically, the objectives were to synthesize the best available evidence on 
the safety and effectiveness of pharmacist prescribing by using doctor prescribing as 
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CHAPTER 2: METHODS 
2.1 Inclusion Criteria 
2.1.1 Participants 
This review considered studies that included patients in a hospital setting, including 
those admitted to hospital, those being assessed prior to elective admission, and 
those being assessed in outpatient clinics. Hospital outpatient clinics were included in 
the review as patients assessed in this setting utilize hospital allocated resources and 
prescribers generally abide by local hospital guidelines and protocols.         
Children and adults of all ages (i.e. from neonates to geriatrics), not limited to any 
specific medical condition or admission reason, who were prescribed medication(s) 
by a pharmacist, were included in this review. 
Studies conducted in settings other than hospitals such as specialist medical centers, 
health maintenance organizations or community clinics were not included in this 
review. In addition, studies that combined data from a hospital with a primary care 
setting were excluded from the review.  
2.1.2 Intervention(s) 
This review considered studies that evaluated all forms of pharmacist prescribing in 
the hospital setting.  
Studies were not considered to meet the inclusion criteria in cases where the 
pharmacist transcribed from one prescription to another, and a doctor review and 
signature was still required on the transcribed prescription before the order was 
considered legitimate.  
2.1.3 Comparator(s) 
This review considered studies that compared the intervention to usual care, i.e. 
prescriptions by hospital doctors. Studies that did not have a comparator group were 
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2.1.4 Outcomes 
This review considered any study that reported the effects of pharmacist prescribing 
on patient outcomes.  
The primary outcome included any of the following reported clinical outcomes: 
• therapeutic failure or benefit, i.e. the effectiveness of medications prescribed to 
control specific disease states, specifically blood pressure, diabetes and 
cholesterol, measured as a change in baseline parameters or the difference 
between arms; 
• number of adverse events related to medications prescribed, i.e. bleeding or 
thromboembolic events; and 
• the incidence of morbidity or mortality related to medication prescribing.  
Secondary outcomes included any of the following: 
• error rates in prescription, specifically incorrect medication choice, dose, 
frequency, or unnecessary medication. Errors were measured by comparison 
to medication histories taken by a pharmacist or by comparison to agreed 
protocols or guidelines; 
• errors of omission due to omission of medication from the medication chart and 
the clinical significance of the omission. Errors of omission were measured by 
comparison of the medication chart to a patient’s medication history taken by a 
pharmacist on admission to hospital while the clinical significance of the 
omission was assessed by an independent panel; 
• requirement in change of prescription by the doctor following prescribing by the 
pharmacist; 
• appropriate dose selection for medications prescribed, where doses were 
considered appropriate when prescribed according to the patient’s medication 
history or an agreed protocol or guideline;  
• time or proportion of International Normalized Ratios (INRs) in therapeutic 
range; 
• time to reach therapeutic range; and 
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2.1.5 Study Types 
This review considered any study with a controlled experimental design for inclusion, 
i.e. randomized controlled trials and quasi experimental prospectively controlled 
trials.  
Studies with a qualitative design, publications not pertaining to primary research or 
papers published in languages apart from English were excluded from the review. 
Studies with lower levels of evidence, such as non-controlled quasi experimental trials 
or observational studies (analytic or descriptive) were excluded as sufficient numbers 
of randomized controlled trials or prospectively controlled quasi experimental trials 
were identified.  
Studies published from database inception up until 24th January 2017 were 
considered for inclusion in this review. Studies were retrieved from time of database 
inception to ensure that all possible relevant studies were included as there is 
variation in the dates that pharmacist prescribing was introduced in different 
countries. 
2.2 Search Strategy 
The search strategy aimed to find both published and unpublished studies. A three-
step search strategy was utilized in this review. An initial limited search in Medline 
and The Cumulative Index to Nursing and Allied Health Literature (CINAHL) was 
undertaken followed by analysis of the text words contained in the title and abstract, 
and of the index terms used to describe the article. This informed the development of 
a search strategy which was tailored for each information source. Full search 
strategies for the databases are detailed in Appendix I.   
A second search using all identified keywords and index terms was then undertaken 
across all included databases on 24/1/2017. A combination of MeSH and keywords 
was used; text variations were set out clearly in a logic grid to enable replicability of 
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Thirdly, the reference lists of all studies selected for critical appraisal were screened 
for additional studies. Other published studies which cited the papers being 
considered for inclusion in the review were also identified using Scopus and reviewed 
to determine if they met the inclusion criteria.   
Information Sources: 
The databases searched included CINAHL, Cochrane Register of Controlled Trials 
(CENTRAL), Embase, PubMed, Scopus and Web of Science Core Collection. 
The search for unpublished studies was performed using Google and Mednar. 
2.3 Study Selection 
Following the search, all identified citations were collated and uploaded into 
Endnote and duplicates removed. Titles and abstracts were screened by the main 
reviewer for relevance to the review topic. Where required, the full-text of the article 
was appraised to determine if it met the inclusion criteria as listed above. Studies that 
met the inclusion criteria were imported into the Joanna Briggs Institute System for 
Unified Management, Assessment and Review of Information (JBI SUMARI).36 Full-
text studies that did not meet the inclusion criteria were excluded and reasons for 
exclusion provided in Appendix II.  
2.4 Assessment of Methodological Quality 
Selected studies were critically appraised by two independent reviewers at the study 
level for methodological quality in the review using the standardized critical appraisal 
instruments from the Joanna Briggs Institute for the following study types: 
Randomized Controlled Trials (Appendix III),37  Quasi experimental Studies (Appendix 
IV).38 Any disagreements that arose were resolved through discussion, or with a third 
reviewer. In some instances, the issue was also discussed with a fourth reviewer, 
usually when clarification or contextualization of the questions in the critical appraisal 
instruments were required. 
Following critical appraisal, studies that did not meet a certain quality threshold were 
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listed in the critical appraisal tools. Two ‘yes’ responses were required for the 
following questions and could be part of the seven ‘yes’ responses: Question 7 
(“Were treatments groups treated identically other than the intervention of interest?”) 
and Question 10 (“Were outcomes measured in the same way for treatment 
groups?”) for randomized controlled trials, and Question 4 (“Was there a control 
group?”) and Question 7 (“Were the outcomes of participants included in any 
comparisons measured in the same way?”) for quasi experimental studies.  
2.5 Data Extraction 
Data was extracted from papers included in the review using the standardized data 
extraction tool available in JBI SUMARI.37,38 The data extracted included specific 
details about the interventions, populations, study methods and outcomes of 
significance to the review question and specific objectives.   
2.6 Data Synthesis 
Statistical meta-analysis was not possible due to heterogeneity between studies and 
therefore the findings were presented in narrative form including tables and figures to 
aid in data presentation where appropriate. 
2.7 Assessing Confidence 
A 'Summary of Findings' table was created using GRADEPro GDT software. The 
GRADE approach for grading the quality of evidence was followed.9 The 'Summary of 
Findings' table ranks the quality of the evidence based on study limitations (risk of 
bias), indirectness, inconsistency, imprecision and publication bias. 
The following outcomes were included in the 'Summary of Findings' table: 
• Therapeutic failure or benefit  
• Prescribing errors 
• Adverse events related to therapy 
• Appropriateness of doses prescribed 
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CHAPTER 3: RESULTS 
3.1 Study Selection 
From the systematic search of the eight databases, reference lists of selected studies 
considered for inclusion and papers which cited selected studies considered for 
inclusion, a total of 22,352 articles were identified for screening (excluding 
duplicates). Following screening of the title and abstract of the articles, 66 papers 
were retrieved for full-text review. Of this number, 50 articles were excluded from the 
review based on the specified inclusion and exclusion criteria. Refer to Appendix II for 
complete list of excluded studies and reasons for exclusion. The 16 remaining articles 
were assessed for methodological quality and were all found to be suitable for 
inclusion in the review. A summary of the studies included in this review is presented 
























































Figure 2: PRISMA Flow Diagram of Search and Study S election Process  
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. 
doi:10.1371/journal.pmed1000097 
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3.2 Description of Included Studies 
The 16 articles included in this review related to 15 studies. Hale et al. (2014) 
reported on a subset analysis of the study by Hale et al (2013).39,40 
Of the 15 included studies, eight were randomized controlled trials,39,41,42,43,44,45,46,47 
and six were prospectively controlled quasi experimental studies.48,49,50,51,52,53 In one 
study,54 the intervention was studied prospectively but patients in the concurrent 
control group were identified retrospectively and data obtained through chart reviews. 
This study was still considered suitable for inclusion as retrospective data collection 
for the control group was deemed unlikely to affect the outcome of the study as usual 
care remained unchanged. The studies were conducted in five countries including 
Hong Kong,41 Canada,54 United Kingdom,48,49 Australia,39,45,47,53 and the United 
States of America,42,43,44,46,50,51,52 with publication dates ranging from 1979 to 2016. 
Seven of the studies recruited less than a hundred participants (range 14 – 
81),42,46,47,49,50,51,54 while the remaining eight studies recruited between 137 to 881 
participants.39,41,43,44,45,48,52,53  
The studies were carried out in the following hospital settings: patients admitted to 
hospital,42,48,49, 50,51,52,53,54 outpatient clinics,41,43,44,46,47 and pre-operative/pre-
admission clinics.39,45 Participants were adults (over 18 years of age) in 13 studies; 
age was not reported in the remaining two studies but participants were likely to be 
adults based on their co-morbidities or reason for admission.50,51 Racial profile was 
reported in five studies, where participants were all Chinese,41 mostly Mexican 
American,43 mostly African American,46 or mostly Caucasian.44,52  
The model of pharmacist prescribing used in the studies included prescribing by 
protocol,41,42,46,48,49,50,51,54  supplementary prescribing,39,44,45,53 and collaborative 
prescribing.43,47 In the remaining study, the model of prescribing used was unclear.52  
Pharmacists prescribed a range of medications including anticoagulants (heparin, 
warfarin, venous thromboembolism prophylaxis in surgical 
patients),39,41,42,48,49,50,51,52,54  antihypertensive medications,43,44,46 antidiabetic 
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pharmacists were not restricted to prescribing any particular class or type of 
medication.39,45,53 
In all studies, pharmacists were prescribing autonomously either according to 
available guidelines, clinical judgement or following discussion with a doctor.  In one 
study, counter signature of prescriptions by a doctor was a site requirement, which 
meant that all patients in the intervention arm were seen by the pharmacist before the 
doctor.39 In another study all patient care assessments and plans made by the 
pharmacist were subsequently reviewed by doctor auditors (not involved in the care 
of any patients in the study) to assure provision of adequate medical care to 
patients.43 The authors of this study reported that plans made by the pharmacist were 
rarely changed by the auditors.    
In most of the included studies, guidelines or dosing nomograms were available to 
guide the pharmacist in the prescribing of medications.  
A warfarin dosing nomogram was used by pharmacists in five studies to adjust 
warfarin dose.41,48,49,50,54 In one of these five studies, dosing nomograms were not 
used by doctors.54 In one study, the pharmacist prescriber could deviate from the 
dosing nomogram if it was deemed necessary according to their clinical judgement.50 
In the remaining studies, dosing nomograms were either not used,42 or it was unclear 
if one was available.52  
In the two studies where heparin was prescribed, a protocol for dosage adjustment 
was available for both pharmacists and doctors in one study;42 in the other study a 
heparin protocol was used by pharmacist prescribers but was not mandatory for 
doctors.51  
In one study, venous thromboembolism prophylaxis for elective surgery patients was 
prescribed according to local and national guidelines in addition to a risk and 
contraindication assessment.39 
In one study, medications for blood sugar, blood pressure and lipid control were 
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In the remaining studies, pharmacist prescribing was based on one of the following: 
protocols which advised on the types of medications which should be withheld 
depending on the nature of the surgical procedure,45 according to national guidelines 
(sixth report of the Joint National Committee on the Detection, Evaluation, and 
Treatment of High Blood Pressure),55 statin (HMG-CoA reductase inhibitor) dose 
adjustment and monitoring algorithm,47 an agreed plan following discussion with the 
doctor.51 All studies included in the review compared pharmacist prescribing to usual 
care, i.e. prescribing by doctors. In some studies, the level of experience of the 
clinicians (pharmacists and doctors) in the two arms varied; e.g. an experienced 
clinical pharmacist versus a junior doctor.48,49 In most other studies where the 
qualification of the doctor was specified, they were at a consultant level and 
specialized in a particular field of medicine.41,42,43,46,50,51,54 The experience level of the 
pharmacist ranged from clinical pharmacists (generalists or otherwise 
unspecified),39,40,41,43,45,47,50,51,53 those who specialized in a particular field (e.g. 
hematology, anticoagulation clinic),42,46,48,49,52,54 to pharmacists with postgraduate 
residency training.44,52 
The outcomes measured in the included studies varied depending on the type of 
medications that were being prescribed by the pharmacist. The primary and 
secondary outcome measures included in this review were dependent on the 
measurable outcomes reported in the included studies. For example, the included 
studies reported on therapeutic failure or benefit in three modifiable disease states, all 
of which were included in this review.      
Primary outcome measures included: 
• Therapeutic failure or benefit with regards to blood pressure control, diabetes 
control, cholesterol control;43,44,46,47  
• Adverse events associated with warfarin or heparin prescribing (bleeding or 
thromboembolic events, death).41,42,49,50,52,54 
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• Prescription errors including medication omissions and the clinical significance 
of the error, incorrect doses, incorrect frequencies, incorrect or unnecessary 
medication;39,40,45,53  
• Requirement for change in prescription by medical prescriber following 
prescribing by pharmacist;39  
• Appropriate prescribing of venous thromboembolism prophylaxis in patients 
being admitted for elective surgery;39  
• For warfarin or heparin prescribing: 
o Appropriate loading and maintenance doses of warfarin prescribed;49,50  
o Number of patients, patient time or proportion of International 
Normalized Ratios (INRs) in, under, or over therapeutic 
range;41,48,49,50,52,54  
o Time to reach therapeutic range;42,49,50,51,54 
• Patient satisfaction.41,46  
3.3 Methodological quality 
The results for the critical appraisal of randomized controlled trials are presented in 
Table 1. In the nine papers which comprised eight randomized controlled trials 
(RCTs), three did not specify the method of randomization used.42,43,46 Of the 
remaining five studies, four used a computer generated randomized list,39,41,44,45 and 
one used random numbers prepared by a clinical pharmacist.47  Allocation to 
treatment groups was reported to be concealed in three studies (two papers) out of 
nine, leading to the potential for distortion of the implementation of the allocation 
process indicated by randomization.39,40,45,47 Treatment groups were deemed to be 
similar at baseline in three studies.42,44,45 In the remaining six studies, baseline 
characteristics differed in terms of gender (more males in the control group),41 age 
(higher mean age in control group),39,47 number of medications on admission,39,40 
baseline diastolic blood pressure (higher in intervention group),46 and baseline fasting 
blood sugar levels (higher in intervention group).43 These differences in baseline may 
indicate a risk of selection bias, which confers a risk that the measured effect 
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(one study) where it was possible to blind participants to treatment assignment.39,40 
This occurred in a pre-operative assessment clinic where patients saw the same four 
health professionals prior to elective surgery.  
Blinding is not possible or very difficult to implement in clinical settings due to the 
nature of the intervention, i.e. pharmacist prescribing, especially in cases where 
patients presented to an outpatient clinic for review by a pharmacist. There were no 
studies where those delivering treatment were blind to treatment assignment. Again, 
this is not possible due to the nature of the intervention. For example, a nurse 
administering medication treatment is easily able to determine whether a pharmacist 
or doctor has prescribed the medication order. However, this is not likely to affect the 
outcome of the study as nursing staff would not have the autonomy to change 
medication orders and medication therapy is administered as ordered by prescriber 
(whether it is a pharmacist or a doctor).  
Two studies (three papers) had outcome assessors that were blind to treatment 
assessment.39,40,45 In most studies, the outcome assessor was not specified, 
increasing the risk of bias in the measurement of outcomes if this had been 
performed by the investigator of the study. Question 7 (“Were treatment groups 
treated identically other than the intervention of interest?”) was scored a ‘yes’ 
provided differences in treatment between groups were considered part of the 
intervention. For example, the intervention was considered identical between groups 
in the case of warfarin prescribing where pharmacists used warfarin nomograms but 
doctors did not. Similarly the intervention was also considered identical if the follow-
up period or clinic appointments varied between doctors and pharmacist prescribers. 
The remaining questions in the appraisal checklist (Q8 to Q13) scored positively in 
78% of cases or above, reflecting good study methodology for follow-up, measures of 
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Table 1: Assessment of Methodological Quality of Ra ndomized controlled Trials 
Citation  Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11 Q12 Q13 Total  
Hale et 
al.39 



































































































































































































































Legend: Q=Question, Y=Yes, N=No, U=Unclear, N/A=Not applicable 
 
The results for the critical appraisal for quasi experimental trials are presented in 
Table 2. All seven quasi experimental trials included in this review had a clear ‘cause’ 
and ‘effect’ that was being measured, a control group and measured the same 
outcome measures reliably. Participants were deemed similar between groups in 
three studies.48,52,54 Patient demographics were not reported in two studies,50,51 and 
reported only for age in one study.49 For the remaining study, participants were older 
in the intervention group.53 Question 5 (“Were there multiple measurements of the 
outcome both pre and post the intervention/exposure?”) scored ‘yes’ in cases where 
multiple INR measurements were taken, even though these INR results were used to 
calculate one single outcome measure (e.g. proportion of INRs within therapeutic 
range). Four studies performed statistical analysis on the outcomes measured. Two 
studies did not calculate statistical significance and one did not specify the method 
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Table 2: Assessment of Methodological Quality of Pr ospectively Controlled 
Quasi experimental Trials 
Citation  Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Total  
Boddy48 Y Y Y Y Y U Y Y Y 8/9 





































































































% 100 43 100 100 86 71 100 100 57  
Legend: Q=Question, Y=Yes, N=No, U=Unclear, N/A=Not applicable 
 
3.4 Findings of the review 
The major findings of this review are reported under five broad categories: therapeutic 
failure or benefit, adverse events related to therapy, appropriateness of prescriptions 
and prescribing errors, anticoagulant prescribing (International Normalized Ratio 
control and time to therapeutic range) and patient satisfaction.  
3.4.1 Therapeutic failure or benefit 
Clinical effectiveness of medication therapy was measured in four randomized 
controlled trials.43,44,46,47 The outcome measures included systolic blood pressure 
(SBP), diastolic blood pressure (DBP), blood sugar levels (BSLs), glycosylated 
hemoglobin (HbA1c), low density lipoprotein (LDL) cholesterol and total cholesterol 
(TC). 
Hawkins et al.43 recruited participants with either diabetes or hypertension, or both. 
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American. Compared to the control group, there was a lower proportion of patients 
with hypertension only (p ≤ 0.04), a higher proportion of patients with both diabetes 
and hypertension (p ≤ 0.025), and higher body mass index values (p < 0.05) in the 
intervention group. Pre-test post-test assessments of blood pressure and fasting 
BSLs were made, with a set of 6 observations used to calculate a mean value. Pre-
test observations occurred in a 12 month period immediately prior to the initiation of 
the study while post-test observations were made between 24 to 29 months after the 
two year study began.  
In Jacobs et al.44 participants with Type 2 diabetes were recruited into the study with 
the majority of patients being Caucasians. As the main inclusion criteria was based 
on HbA1c, not all patients had a clinical diagnosis of hypertension at baseline. A 
similar number of patients in both groups had a diagnosis of hypertension or 
dyslipidemia. Pre-test and post-test measurements of blood pressure, HbA1c and 
LDL cholesterol were made at baseline and 6 and 12 months (+/- 1 month) of the 
study period. For the purposes of this review, only observations at the 12 month 
period are discussed in detail to ensure maximum benefit of medication therapy had 
been achieved at the time the endpoint was measured.  
Vivian46 recruited participants with essential hypertension into the study. All 
participants were male and a high proportion (77%) was African-American. There was 
a lower percentage of patients with diabetes (42% versus 59%) and a lower 
percentage of smokers (15% versus 26%) in the intervention group compared to the 
control group. Blood pressure was measured at baseline and 6 months later. 
Weeks and Fyfe.47 recruited patients with peripheral vascular disease who had raised 
LDL cholesterol. Patients were seen by the pharmacist every 6 weeks and were 
provided with lifestyle advice at each visit. It is unclear if patients in the doctor group 
were also provided with advice on non-medication measures to reduce cholesterol at 
each visit. Pre-test and post-test LDL and total cholesterol were measured at baseline 
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3.4.1.1 Blood Pressure control 
Three studies measured blood pressure control to evaluate the effect of pharmacist 
prescribing on the outcomes of patient care.43,44,46 Participants were all male and 
mostly African Americans in one study,46 mainly Mexican-American in another,43 and 
mainly Caucasian in the remaining study.44 Due to heterogeneity in study 
methodology (analytical method) and population, no meta-analysis was performed. A 
narrative description of the studies follows.    
In all three studies, the difference in means of post-test assessment between the two 
groups was used to measure the significance of the difference between arms. In two 
studies, there was a significant difference in baseline blood pressure for either SBP or 
DBP between the intervention and control group.44,46 This was not adjusted for in the 
analysis thus the outcome analysis using difference in means of post-test blood 
pressure may be inaccurate. 
One study also calculated the significance of the change in mean blood pressure from 
baseline for both groups.46 In this study, the mean SBP change from baseline which 
was reported narratively differed slightly from that which can be calculated from the 
pre-test and post-test data presented in the paper, and is reflected in Table 3. Mean 
SBP and mean DBP changes from baseline were also presented in the table but 
statistical significance was not able to be calculated as there were insufficient data 
presented in the papers.   
Two studies also reported on the number of patients who achieved target blood 
pressure at the end of the study.44,46 
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Table 3: Pre-test and Post-test Systolic Blood Pres sure (SBP) and Diastolic 
Blood Pressure (DBP) 





Mean SBP (mmHg) 
Control  





Pre-test Post-test Pre-test Post-test   
Hawkins 
et al.43  
RCT 
145 ± 15 147 ± 18 143 ± 14 141 ± 13 +2 -2 
Pre-test: Not statistically significant  











135.4 ± 14 -10 +0.6 
Pre-test: p = 0.03 








14.3 148.4 ± 21 
-18.4 (95% CI, 
-26.3, -10.5) 
-3.98 (95% CI,   
-11.8, 3.79) 
Pre-test: p = 0.252 
Post-test: p = 0.0002 
p = 0.01 
 




Mean DBP (mmHg) 
Control  




Pre-test Post-test Pre-test Post-test 
Hawkins 
et al.43  
RCT 
86 ± 6 84 ± 6 86 ± 6 84 ± 4 -2 -2 





79.4 ± 9.9 72.0 ± 8.5 78.3 ± 10.4 77.6 ± 8.4 -7.4 - 0.7 
Pre-test: p = 0.493 








77.9 ± 11.9 80.4 ± 11.4 
-12.3 (95% CI, 
-16.49, -8.28) 
+2.5  (95% CI,    
-1.49, 6.57) 
Pre-test: p = 0.0012 
Post-test: p = 0.259 
p = 0.001 
Legend: RCT=Randomized controlled Trial 
 
In Hawkins et al.43, there was an increase in post-test mean SBP from baseline in the 
intervention group, which was statistically significant (p ≤ 0.001). This was in direct 
contradiction to the goal of blood pressure reduction in this study. There were no 
statistically significant differences between pre-test and post-test DBP. It is possible 
that the increase in SBP in the intervention group could be due to the higher number 
of patients who had both hypertension and diabetes compared to the control group. A 
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study participants between the two groups and therefore these results should be 
interpreted with caution.  
In the study by Jacobs et al.44, there was a significant difference in the pre-test mean 
SBP between both groups, with baseline mean SBP higher in the intervention group 
(p = 0.03). There was also a higher proportion of patients in the intervention group 
who were smokers, had a family history of premature heart disease, hypertension, 
coronary heart disease and dyslipidemia which may account for the higher baseline 
SBP, although these differences did not reach statistical significance.  Post-test SBP 
was not found to be significantly different between groups (p = 0.223). As not all 
patients had a clinical diagnosis of hypertension at baseline, the findings that patients 
in the intervention arm had a mean SBP reduction of 10 mmHg compared to an 
increase of 0.6 mmHg in the control arm is not surprising, as more patients in the 
control arm were closer to being normotensive at baseline. There was a significant 
reduction in post-test mean DBP in the intervention group compared to the control 
group (p = 0.001). Differences in patient characteristics between groups were not 
adjusted for in the outcome analysis, thus adjusted effects were not reported. 
The study by Vivian found post-test SBP in the intervention group was significantly 
lower compared to the control group (p = 0.0002).46 For DBP, there was a significant 
difference in baseline mean between groups, with mean DBP higher in the 
intervention group (p = 0.0012); the reason for this difference is unclear. Post-test, no 
significant differences in DBP were found between arms (p = 0.259). A separate 
analysis was conducted for patients with diabetes but as diabetic patients accounted 
for approximately 50% of the total participants, these results reflected the overall 
study findings. The results were not adjusted for patient mix.  
In the outcome analysis conducted by Vivian, mean changes in SBP and DBP from 
baseline for both groups were also compared. Mean SBP reduced by 18.4 mmHg in 
the intervention group compared to 3.98 mmHg in the control group, a finding that 
was statistically significant (p = 0.01). Mean DBP reduced by 12.38 mmHg in the 
intervention group compared to an increase in 2.54 mmHg in the control group, a 
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Two studies reported patient numbers achieving a predefined target blood pressure, 
The study by Vivian which recruited patients with hypertension with or without 
diabetes, used target blood pressure of 140/90 mmHg.46 The number of patients who 
achieved this target was 21 (81%) in the intervention group and eight (30%) in the 
control group, a finding that was statistically significant (p = 0.001). The study by 
Jacobs et al. which recruited patients with type 2 diabetes only, had a lower target 
blood pressure of equal to or below 130/80 mmHg.44 The study found that at 12 
months, target SBP was met in 29 patients (51%) in the intervention group and 30 
patients (43%) in the control group, while target DBP was met in 48 patients (84%) in 
the intervention group and 54 patients (77%) in the control group. Both of these 
findings were not statistically significantly different between groups and the clinical 
significance was not discussed.  
Summary 
One study found that pharmacist prescribers were better at blood pressure 
management than doctors but the clinical significance of this was not discussed. In 
the remaining two studies, patient-mix adjustment was not made to account for 
differences in baseline characteristics and therefore no conclusion can be drawn from 
these studies.  
3.4.1.2 Diabetes control 
Two studies measured diabetes control to evaluate the effect of pharmacist 
prescribing on the outcomes of patient care.43,44 Due to heterogeneity in study 
methodology (analytical method) and population, no meta-analysis was performed. 
Heterogeneity between studies was mainly due to differences in the race and gender 
of participants included in the two studies. The study population in Hawkins et al.43 
was mainly Mexican-American with over 75% being female while those in Jacobs et 
al.44 were mainly Caucasian. A narrative description of the studies follows. 
In both studies, the difference in means of post-test assessment between the two 
groups was used to measure the significance of the difference between arms. One 
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(HbA1c) from baseline for both groups.44 The remaining study did not present results 
for mean change in fasting BSL from baseline. Statistical significance was not able to 
be calculated as there were insufficient data presented in the paper.   
Results for mean fasting BSL and HbA1c measured are summarized in Table 4. 
 
Table 4: Diabetes Control 
Study 
details 
Mean fasting BSL  Mean change from baseline  
Intervention (mg/dL)  Control (mg/dL)  Intervention 
(mg/dL) 
Control  




192 ± 46 184 ± 42 182 ± 39 189 ± 49 -8 +7 
Pre-test: p ≤ 0.05,  





Mean HbA1c  Mean change from baseline  
Intervention (%)  Control (%)  
Intervention (%)  Control (%)  
Pre-test Post-test Pre-test Post-test 
9.5 ± 1.1 7.7 ± 1.3 9.2 ± 1.0 8.4 ± 1.6 -1.8 -0.8 
Pre-test: p = 0.07 
Post-test: p = 0.003 
p < 0.05 
Legend: RCT=Randomized controlled Trial 
 
In the study by Hawkins et al.43, the intervention group had a significantly higher 
baseline mean fasting BSL (p ≤ 0.05), which was adjusted using an analysis of 
covariance (ANCOVA). Analysis of covariance is a regression method which adjusts 
each patient’s post-test measure for their baseline measure, with the advantage of 
being unaffected by baseline differences between groups.56 This analysis showed no 
significant difference in mean fasting BSLs between arms post-test (p = 0.058). The 
differences in baseline BSL between groups is likely to be due to the higher 
proportion of patients who were both hypertensive and diabetic in the intervention 
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levels. Both arms had the same proportion of patients with diabetes without a 
diagnosis of hypertension.  
Jacobs et al.44 found that post-test mean HbA1c was no different between arms at the 
end of six months, with mean HbA1c 8.1 +/- 1.2 % in the intervention group and 8.2 
+/- 1.2 % in the control group (p = 0.597). However, at the end of 12 months, mean 
HbA1c was significantly lower in the intervention arm (p = 0.003). Mean change in 
HbA1c from baseline to 12 months post-test in both groups was also compared, with 
a reduction of 1.8% in the intervention group compared to an increase in 0.7% in the 
control group, a finding that was statistically significant (p < 0.05). The clinical 
significance of these findings were not discussed. 
One study also reported patient numbers achieving a predefined target glycosylated 
hemoglobin of equal or less than 7%.44 At the end of 12 months, 19 patients (35%) in 
the intervention group achieved this target compared to 14 patients (21%) in the 
control group. This finding was not found to be statistically significant (p = 0.105).  
Summary 
Pharmacist prescribers manage blood sugar control in diabetics just as well as 
doctors. In one study pharmacist prescribers were statistically significantly better at 
managing blood sugar than doctors, although the clinical significance was not 
discussed.  
3.4.1.3 Cholesterol control 
Two studies measured cholesterol control to evaluate the effect of pharmacist 
prescribing on the outcomes of patient care.44,47 In Jacobs et al.44, LDL cholesterol 
was the outcome measure while both LDL cholesterol and total cholesterol were 
measured by Weeks and Fyfe.47 The results of these studies are presented in Table 
5. 
Meta-analysis was not performed for LDL cholesterol due to the small number of 
study participants in Weeks and Fyfe47 (six in control, eight in intervention). Due to the 
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intervention), more weight would be assigned to this study, which would mask any 
study effects by Weeks and Fyfe.47 
Mean LDL cholesterol in Jacobs et al.44 was reported in mg/dL but was converted to 
mmol/L to allow comparison between studies. At the end of the trial, the intervention 
group was found to have a significantly lower LDL cholesterol compared to the control 
arm (p = 0.01) but the clinical significance of these results were not discussed.  
 
Table 5: Low Density Lipoprotein (LDL) Cholesterol and Total Cholesterol 
Mean LDL  Mean change from baseline  
Study  
details 
Intervention  (mmol/L)  Control (mmol/L)  Intervention  
 (mmol/L) 
Control  




3.1 ± 0.8  2.4 ± 0.5  3.0 ± 0.9  2.7 ± 0.9  -0.7 -0 .3 
Pre-test: p = 0.227 





3.1 1.8 3.1 2.9 -1.3 -0.2 
No statistical analysis performed (sample size too 
small) 
 
Mean Total cholesterol  Mean change from baseline  
Study  
details  
Intervention (mmol/L)  Control (mmol/L)  Intervention  
 (mmol/L)  
Control  




5.1 4.0 5.3 5.2 -1.1 -0.1 
No statistical analysis performed (sample size too 
small) 
 
Legend: RCT=Randomized controlled Trial 
 
Weeks and Fyfe also reported an improvement in LDL cholesterol in both arms, with 
patients managed by the pharmacist prescriber lowering their LDL cholesterol by 1.3 
mmol/L compared to 0.2 mmol/L in the doctor group.47 There was also a greater 
reduction in total cholesterol for patients in the intervention arm compared to the 
control arm (1.1 mmol/L versus 0.1 mmol/L). The results of this study could also 
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adhering to the treatment plan for cholesterol lowering. Due to the small sample size, 
no statistical analysis was performed in this study and caution should be used when 
interpreting the results.  
Jacobs et al.44  also reported patient numbers achieving a predefined target LDL 
cholesterol of equal or less than 100 mg/dL (2.6 mmol/L). At the end of 12 months, 32 
patients (62%) in the intervention group achieved this target compared to 24 patients 
(55%) in the control group. This finding was not found to be statistically significant (p 
= 0.537).  
Summary 
There is some evidence to suggest that pharmacist prescribers can manage 
cholesterol levels at least as well as doctors, with improvement in LDL cholesterol 
and total cholesterol. One study found patients of pharmacist prescribers had 
statistically significantly lower LDL post-test than patients of doctors, but the clinical 
significance of this was not reported.  
Overall Summary – Clinical effectiveness 
Pharmacist prescribers manage blood pressure, blood sugar and cholesterol levels 
just as well as doctors. In studies that reported measured endpoints, these were 
statistically significantly lower in the pharmacist prescriber group, although the clinical 
significance was not discussed.  
3.4.2 Adverse events related to therapy 
The six studies (two randomized controlled trials and four prospectively controlled 
quasi experimental studies) that reported adverse events as an outcome were all 
related to warfarin therapy and associated bleeding or thromboembolic 
events.41,42,49,50,52,54 The classification of adverse events by severity occurred in some 
studies but not in others. Where classification of severity occurred, the definition of 
what constituted major or minor bleeding differed. All studies were underpowered to 
detect adverse effects related to therapy, mainly due to small effects but also small 
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performed. A narrative description of the studies follows and the results are presented 
in Table 6. 
 
Table 6: Adverse Events related to Warfarin Therapy      




Minor  Major  
Int  Cont  Int  Cont  Int  Cont  Int  Cont  
Chan et al.41 
RCT 




1 (1.6 ppy) 1 (1.6 ppy) 0 0 






0 0 0 Not reported 0 0 




Combined bleeding/thromboembolic events: 
Int: 6% (2 strokes) 
Cont: 12% (1 stroke and 3 bleeding events) 






2 (7%) 3 
(14%) 
0 0 0 0 0 0 
Significance not reported 
Schillig et al.52 
Quasi 
experimental 
Not reported 2 (0.8%) 1 (0.4%) 0 0 0 0 
 p = 0.563    
Chau et al.54  
Quasi 
experimental 
1 (3%) 2 (6%) 0 2 (6%) 0 1 (2%) 0 1 (2%) 
Significance not reported 
Legend: Int=Intervention, Cont=Control, ppy=per 100 patient-years, RCT=Randomized controlled Trial 
 
Chan et al.41 reported the number of major bleeding events to be one (1.6 per 100 
patient-years) in the intervention group and two (3.1 per 100 patient-years) in the 
control group, a finding that was not statistically significant (p = 1.0). No fatalities 
occurred due to bleeding in either group. The number of major thromboembolic 
events was one (1.6 per 100 patient-years) in both arms, a finding that was also not 
statistically significant (p = 1.0). No fatalities related to thromboembolic events 
occurred in either group. 
Chenella et al.42 found that four patients (10%) in the intervention arm suffered from 
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events occurred in either arm. The significance of these findings was not reported. 
This study did not report thromboembolic events as a study outcome.  
Burns reported the combined total of adverse events, which equated to 6% (two 
strokes) in the intervention arm and 12% (one stroke and three bleeding events) in 
the comparator arm.49 The significance of this finding was not reported.  
Chau et al.54 reported the number of bleeding events (minor and major), the number 
of venous thromboembolisms and number of deaths that occurred in each arm. Minor 
bleeding events occurred in one (3%) and two (6%) patients in the intervention and 
comparator arm bleeding respectively. There were no occurrences of major bleeding 
events in the intervention arm compared to two (6%) in the comparator arm. No life-
threatening bleeding events occurred in either arm. No pulmonary embolisms or 
deaths were reported in the intervention arm while one patient (2%) in the comparator 
arm developed a pulmonary embolism which resulted in death. Deep vein thrombosis 
was not reported in either arm. Both statistical and clinical significance of the findings 
was not reported. 
Damaske and Baird reported that two (7%) bleeding events occurred in the 
intervention arm and three (14%) in the comparator arm.50 All events were considered 
minor by the attending doctors. The statistical and clinical significance of this finding 
was not reported. No other adverse events occurred in either arm. 
In Schillig et al.52, two (0.8%) major bleeding events occurred in the intervention arm 
compared to one (0.4%) in the comparator arm. This finding was not statistically 
significant (p = 0.563). No thromboembolic events occurred in either group. 
Summary 
For all studies, outcome data for bleeding or thromboembolic events were small. 
Bleeding events were classified by severity except in the case of Burns where 
combined bleeding and thromboembolic events were reported.49 Where statistical 
analysis was performed, no significant differences were found between the control 
and intervention group.41, 52 In the remaining four studies which did not perform 
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the results is difficult due to the small number of events.42,49,50, 54 In all cases, the 
studies were underpowered to detect a difference in incidence of adverse effects 
between the intervention and control groups and therefore a meaningful conclusion 
cannot be drawn.  
3.4.3 Appropriateness of prescriptions and prescrib ing errors  
A number of studies reported appropriateness of medication orders prescribed, 
prescribing errors and medications omitted from the medication chart. This is 
discussed in further detail below, with a summary of the results presented in Table 7.  
 








Intervention  Control  P value  




















































F (1, 26) = 
17.33, p < 
0.001 
Damaske 





prescribed first dose 










test: p = 0.21 
Legend: RCT=Randomized controlled Trial 
 
3.4.3.1 Appropriateness of medication orders prescribed 
One randomized controlled trial and two quasi experimental studies reported 
appropriateness of prescribing as an outcome measure.39,49,50  Due to heterogeneity 
in study methodology, population and the outcome measured, no meta-analysis was 
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In the randomized controlled trial by Hale et al.39, appropriateness of venous 
thromboembolism (VTE) prophylaxis (chemical or mechanical) was assessed in 
tandem by two assessors and rated in accordance with local and national guidelines. 
There was a statistically significant difference (p < 0.001) between percentages of 
appropriate VTE prophylaxis prescriptions in the intervention arm (93.8%) compared 
to the control arm (63.9%) in the preadmission clinic. There was no statistical 
difference between arms when the prescriptions were assessed for patients on 
admission with 93.1% prescriptions deemed appropriate in the intervention arm 
compared to 89.5% in the control arm.  
Burns found that for patients who required a loading dose with warfarin, all 14 
patients (100%) were dosed appropriately in the intervention group compared to 11 
(73%) in the comparator group.49 The statistical significance of these findings was not 
reported by the authors but a Fisher’s exact test showed no statistically significant 
difference between groups (p = 0.1). Following a loading dose with warfarin, the 
number of patients who received an appropriate maintenance dose was 14 (100%) in 
the intervention group and seven (46%) in the comparator group, a finding that was 
statistically significant (p < 0.001)  
In Damaske and Baird, all 29 patients (100%) in the intervention arm were dosed 
appropriately with warfarin compared to 15 patients (68%) in the comparator arm.50 
The significance of these findings was not reported by the authors but a Fisher’s 
exact test showed no statistically significant difference between groups (p = 0.21). 
Summary 
There was no difference in the appropriateness of warfarin prescribing between 
pharmacists and doctors except in the prescribing of maintenance doses in one study 
where pharmacists were found to be more compliant with existing guidelines. In the 
prescription of VTE prophylaxis, pharmacists were found to be better at following 
recommended guidelines than doctors when the medication charts were assessed in 
a preadmission clinic. However, there were no differences between prescribing arms 
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3.4.3.2 Prescriptions requiring modification by a doctor 
Three randomized controlled trials reported on prescriptions which required 
modification by a doctor subsequent to pharmacist prescribing, by either comparing 
prescribing between arms or by auditing management plans made by the 
pharmacist.39,40,42,43 Meta-analysis was not possible so a narrative description of the 
studies follows. 
Hale et al.40 reported that of the 194 patients prescribed medications by the 
pharmacist in the intervention arm, 10 charts were amended by a doctor. Of this 
number, five were considered minor changes and three were addition of analgesics 
which were out of the pharmacist’s prescribing scope. The remaining two changes 
were related to venous thromboembolism prophylaxis, of which a change by the 
doctor resulted in inappropriate VTE prophylaxis according to local and national 
guidelines. 
In Chenella et al.42, patients were prescribed anticoagulants (heparin and warfarin) by 
the doctor group or the pharmacist-prescriber group. With each prescription, the 
clinician in the other arm simulated prescribing in a blinded fashion on a data 
collection sheet. The simulated dose was not disclosed to the clinician in the other 
arm, or administered to the patients. Regression lines were used to compare actual 
and simulated doses for patients in both groups and were found to be closely 
correlated for both heparin and warfarin in each arm.  
In Hawkins et al.43 all patient-care assessments and plans made by the pharmacist 
were subsequently reviewed by doctor auditors to assure the provision of adequate 
medical care to patients, A prospective evaluation of doctor acceptance of the 
pharmacist’s plans during the first 18 months of the study showed that 99% of these 
plans were accepted without modification.      
Summary 
Where doctors independently assessed pharmacist prescribing, they were mainly in 
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3.4.3.3 Prescribing errors 
Two randomized controlled trials and one quasi experimental study included in this 
review included prescribing errors as an outcome measure.39,40,45,53 In all three 
studies, the prescribing errors reported were clinical errors (e.g. errors in prescription 
of a medication, dose, frequency or route) which can potentially lead to error in the 
medication administered to the patient, resulting in clinically significant adverse 
events. This is distinguished from documentation errors (e.g. unsigned prescription, 
date of prescription omitted) which does not usually lead to an error of clinical 
significance. A meta-analysis of clinical errors reported in three studies was not 
possible as one randomized controlled trial provided insufficient data to allow this.45 
These results are summarized in Table 8.  
A narrative description of the studies follows. 
Hale et al.39 defined prescribing errors as those related to medication, dose or 
frequency, and communication errors as prescriptions that were rated as ambiguous 
or unclear. The study found significantly less prescribing errors (p < 0.001) in the 
intervention group (0.2% of orders) compared to the control group (6.3% of orders).  
A sub analysis of 5% of trial participants (randomized sample) in Hale et al.39 (2013) 
was reported in Hale et al.40 (2014). A panel, blinded to patient allocation, was 
convened to assess the appropriateness of prescriptions and a modified Medication 
Appropriateness Index was used to assess the appropriateness of prescribing.57 
Based on the overall combined assessment of all panel members, the number of 
prescriptions deemed inappropriate was 13 from 266 prescriptions (4.9%) in the 
intervention arm and 32 from 294 prescriptions (10.9%) in the control arm. The 
significance of this finding was not reported but analysis using Fisher’s exact test 
shows a statistically significant difference between groups (p = 0.01). Based on 
individual reviewers’ assessments, the difference in groups was only statistically 
significant when assessed by the pharmacist, with six of 61 medications assessed as 
inappropriate in the control arm compared to zero of 64 in the intervention arm (p = 
0.029). Assessments by the remainder of the panel which consisted of an anesthetist, 
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statistically significant difference in the number of inappropriate medications between 
arms. Total number of medications reviewed by each individual assessor and total 
number of medications rated as inappropriate by each assessor (apart from that of 
the pharmacist) were reported as a combined number for the intervention and control 
group, and therefore further comparison between arms was not possible. 
Marotti et al.45 reported on incorrect doses and incorrect frequencies of medications 
charted. Outcome measures were collected by an independent technician. The 
average number of incorrect doses was found to be 0.02 and 0.48 in the intervention 
and control groups respectively (p < 0.05). The average number of incorrect 
medication frequencies charted was 0.015 and 0.29 in the intervention and control 
groups respectively (p < 0.05).  
Tong et al.53 defined medication errors as prescriptions with an omitted medication, 
incorrect dose or frequency, incorrect or unnecessary medication or incorrect 
medication route), which were detected within 24 hours of admission. Errors were 
identified by an independent pharmacist assessor who was not blinded to 
randomization. These errors were then reviewed and assigned a risk rating by a 
blinded independent expert panel comprising a general doctor, an emergency doctor 
and a senior clinical pharmacist. The study found that the number of patients with 
medication errors were 15 (3.7%) in the intervention arm and 372 (78.8%) in the 
comparator arm, a finding that was statistically significant (p < 0.001). The number of 
errors detected per patient was also significantly lower in the intervention arm (p < 
0.001) – pharmacist prescribers made no errors in 393 patients (96.3%) and did not 
make more than two errors per patient. In the comparator arm, doctors made no 
errors in 101 patients (21.3%) and five errors or more in 126 patients (26.6%). Errors 
were then classified as insignificant, low risk, moderate risk, high risk or extreme risk 
(catastrophic), defined as follows: 
• “Insignificant: No harm or injuries; low financial loss 
• Low: Minor injuries, minor treatment required, no increased length of stay or 
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• Moderate: Major temporary injury, increased length of stay or re-admission, 
cancellation or delay in planned treatment or procedure. Potential for financial 
loss 
• High: Major permanent injury, increased length of stay or readmission, 
morbidity at discharge, potential for significant financial loss 
• Catastrophic: Death, large financial loss and/or threat to goodwill/good name” 
.58(p.S45) 
Pharmacists made significantly less errors in all categories (p = 0.01), with four errors 
(1%) classed as moderate risk, one error (0.2%) as high risk and no errors that 
conferred extreme risk to the patient. In contrast, doctors were found to have made 
81 errors (17.1%) of moderate risk, 150 errors (31.7%) of high risk and 25 errors 
(5.3%) of extreme risk. The most frequently made error in both groups was for 
medicines omitted from the medication chart. The authors reported on a ‘number to 
treat’ analysis, which found one case of high risk or extreme error was prevented for 
every three patients reviewed and prescribed medications by the pharmacist. 
Summary 
All three studies found that pharmacist prescribers made significantly less clinical 
prescribing errors than doctors. In two studies, the results were unlikely to be 
influenced by assessor bias as the outcome assessors were blinded to patient 
allocation. In a sub analysis of one study, no difference was found in 
inappropriateness of prescriptions between arms. One study found that pharmacist 
prescribers had less patients with medication errors, fewer errors per patients and 
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Table 8: Prescribing Errors: 
Study 
details  Errors assessed 
Results  
Intervention Control P value  
Hale et al.39 
RCT 
 
Incorrect medication, dose or 
frequency 
(total number)  
2 (0.2%) 51 (6.3%) 
p < 0.001 
Communication errors  















p < 0.05 
Incorrect frequencies charted  
(average number) 
0.015  




p < 0.05 









Zero errors 393 (96.3%) 101 (21.3%) 
p < 0.001 One to two errors 15 (3.7%) 145 (30.6%) 






Severity rating 1 or 2 
(Insignificant to low 
risk) 
10 (2.4%) 116 (24.5%) 
p = 0.01 
Severity rating 3 or 4 
(Moderate to high risk) 5 (1.2%) 231 (48.8%) 
Severity rating 5  
(Extreme risk) 





Omitted medication 12 1397 
p < 0.01 
Incorrect dose 7 138 




Incorrect route 0 0 
Legend: RCT=Randomized controlled Trial 
 
3.4.3.4 Medication Omissions 
Four papers (related to three studies) included in this review also reported on 
medication omissions separately to prescribing errors as an outcome measure. Due 
to the different study methodologies (two randomized controlled trials,39,40,45 one quasi 
experimental trial),53 the results were not combined in a meta-analysis. A narrative 






P a g e  | 58 
Table 9: Medication Omissions: 
Study 
details 




Intervention Control P value 
Hale et al.39  
RCT 
Regular medications 3/887 (0.3%) 
248/1217 
(20.4%) 
p < 0.001 





test: p < 0.0001 
Hale et al.40 
RCT 




Not specified as regular or ‘when 
required’ medications (Mean 
number) 
1.07 (95% CI 
0.9-1.25)  
3.21 (95% CI 
2.89-3.52) p = 0.002 
Tong et al.53  
Quasi 
experimental 
Not specified as regular or ‘when 
required’ medications 
12 1397 p < 0.01 
Legend: RCT=Randomized controlled Trial 
 
In Hale et al.39, the total number of medications omitted form the prescription chart in 
the intervention group was 11 (1.2%), of which three (0.3%) were regular medications 
and eight (0.9%) were PRN (when required) medications. In the control group, there 
were a total of 383 medications (31.5%) omitted from the prescription chart, of which 
248 (20.4%) were regular medications and 135 (11.1%) PRN medications. The 
difference between arms for regular medications was statistically significant (p < 
0.001). The odds ratio for an order in the control group to be omitted, compared to the 
intervention group, was 41.0 (95% CI, 20.6, 81.8; p< 0.001). This analysis was 
adjusted for the total number of medications patients were taking, which was higher in 
the control group than in the intervention group (1364 versus 983). Results were not 
adjusted for patient mix. A greater number of medicines in the control arm biases the 
study to pharmacist prescribing and while adjustments were made, residual 
confounding may still be present. The statistical significance of the difference 
between arms for PRN medications was not reported but p value was calculated to be 
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In a subset analysis of 5% of the patient population in study by Hale et al.40, the 
number of regular medications omitted from the chart was found to be one out of 55 
(2%) for the intervention group and 25 out of 89 (28%) in the control group which was 
statistically significant (p < 0.001). The clinical significance of medication omissions 
was assessed by an independent panel; only one of six reviewers thought the single 
occurrence of omission was significant. In the control group, the average across the 
panel showed just under half of omissions had the potential to cause patient harm.  
Marotti et al.45 found that the mean number of medications omissions was 1.07 in the 
intervention group and 3.21 in the control group, a finding that was statistically 
significantly different (p = 0.002). 
In Tong et al.53, the number of medication omissions was 12 in the intervention group 
and 1397 in the comparator group, a finding which was statistically significant (p < 
0.01). 
Summary 
In three studies, the pharmacist prescriber group made less medication omissions 
compared to the doctor group. In one study, nearly half of the medication omissions in 
the control group were judged to have the potential to cause patient harm.  
Overall Summary – Appropriateness of prescriptions and prescribing errors 
The evidence shows pharmacists prescribe warfarin doses just as well as doctors; 
there is some evidence to suggest that pharmacists adhere to dosing guidelines 
better than doctors. 
When studied, pharmacists make significantly less clinical prescribing errors than 
doctors, in addition to having fewer errors that confer a moderate, high, or extreme 
risk to the patient. 
Doctors were mainly in agreeance with therapeutic plans made and doses prescribed 
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Pharmacist prescribing resulted in significantly less medication omissions compared 
to doctor prescribing; nearly half of medication omissions by doctors were rated to 
have the potential to cause patient harm compared to none in the pharmacist 
prescribing arm. 
3.4.4 Anticoagulant Prescribing – International Nor malized Ratio (INR) control 
and time to therapeutic range 
3.4.4.1 INR in therapeutic range 
Of the seven studies on warfarin prescribing, one randomized controlled trial and 
three quasi experimental studies reported INR in therapeutic range as an outcome 
measure.41,48,49,54 However, these studies varied in their measurements of the 
outcome, either at the time of measure (e.g. Day 4 versus at discharge) or by unit of 
measure (e.g. patient-time within range versus percentage patients or INR within 
range). Due to heterogeneity in populations and the outcome measured, no meta-
analysis was performed. A narrative description of the studies follows. 
Chan et al.41 reported that patient-time spent within target INR range was 64% for the 
intervention group and 59% for the control group, a statistically significant difference 
(p < 0.001).  Patient-time in extended target range (defined as +/- 0.2 INR units) was 
78% and 76% for the intervention and control arm respectively, a finding that was 
also statistically significant (p < 0.001).  
In Boddy, the percentage of INRs within target range from Day 4 onwards was 58% in 
the intervention group and 18% in the control group, which was statistically significant 
(p < 0.001).48 
Burns found that for patients who required loading with warfarin, the percentage who 
were within target range on Day 4 after loading was 57% for the intervention group 
and 46% for the comparator group (p = 0.72).49 On discharge or transfer to another 
ward, 68% of patients in the intervention arm were within target range compared to 
73% in the comparator arm (p = 0.77). At the outpatient clinic, 61% of patents in the 
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(p = 0.32). The statistical significance of these findings was not reported by the 
authors; p values reported above were calculated using Fisher’s exact test.  
Chau et al.54 reported that the proportion of INRs within target range was 67.9% in the 
intervention arm and 50.9% in the comparator arm. The statistical significance of this 
was not reported; Fisher’s exact test could not be used to calculate the p value as the 
total number of INR tests performed was not reported.  
Summary 
The four studies described above were conducted in different hospital settings (one 
outpatient clinic and three inpatient wards) in adult patients of varying ages (one 
study in elderly patients and one excluding elderly patients). In one study, all study 
participants were Chinese. Patients were admitted under medical units or 
rehabilitation units (following orthopedic intervention or stroke). In one study,54 
doctors did not have access to a warfarin dosing nomogram while the pharmacist 
prescribers did. In the remaining three studies, both arms used a warfarin dosing 
nomogram.  
Two studies show a statistically significant improvement in INR in therapeutic range in 
the pharmacist prescriber group compared to usual care by doctors.41,48 Another 
study showed improvement in the intervention arm but the statistical significance was 
not reported.54 The remaining study did not show any statistically significant 
differences between arms at any stage of the patient journey.49 These results indicate 
that pharmacist prescribers are able to maintain INR in therapeutic range just as well 
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Measurement Unit and Time of Measure 
Results  
Intervention  Control  P value  




Patient time  64% 59% p < 0.001 
Patient time in extended 
target INR range (+/- 0.2 
INR units) 






Percentage INRs from Day 
4 onwards 




Percentage INRs < 2.0 






Percentage INRs > 6.0 







Percentage patients on 
Day 4 after loading 




test: p = 0.72 
Percentage patients on 







test: p = 0.77 
Percentage patients at the 
Outpatient clinic 




test: p = 0.32 
Sub- or supra-
therapeutic 
Percentage patients (+/- 
0.2 INR units) 67% (22/33) 
91% 
(30/33) 
F (1, 64) = 
6.17, p = 
0.016 
Damaske 











Percentage INRs > 5.0 9.6% 14.8% p = 0.076 










Percentage INRs < 2.0 22.7% 33.2% 
Supra-
therapeutic 
Percentage INRs 3.01 –
3.99 9.1% 12.8% 
Percentage INRs 4.0 – 6.0 0.3% 2.1% 
Percentage INRs > 6.0 0% 0% 
Legend: RCT=Randomized controlled Trial 
3.4.4.2 Subtherapeutic or Supratherapeutic INR  
Five controlled quasi experimental trials reported INR above or below therapeutic 
range as an outcome measure.48,49,50,52,54 However, these studies varied in their 
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versus > 5.0 versus > 6.0). The studies also varied in the reported unit of measure 
(e.g. percentage INRs versus percentage patients). Due to heterogeneity in 
populations and the outcome measured, no meta-analysis was performed. A narrative 
description of the studies follows. 
In Boddy,48 INRs below 2.0 and above 6.0 from Day 4 onwards were outcome 
measures of interest. In most clinical scenarios, an INR below 2.0 is considered 
subtherapeutic and puts the patient at risk of thromboembolic events. In all cases, an 
INR above 6.0 is considered supratherapeutic and increases a patient’s risk of 
bleeding. The percentage of INRs below 2.0 was 10% in the intervention arm and 
32% in the comparator arm while the percentage of INRs above 6.0 was 1% in the 
intervention arm and 5% in the comparator arm. Statistical significance was not 
reported and there was no discussion of the clinical significance of these results.  
Burns reported on the percentage of patients who had a subtherapeutic or 
supratherapeutic INR (+/- 0.2 INR units) at some point during their stay.49 In the 
intervention arm, 67% patients were either under- or over-anticoagulated compared to 
91% patients in the comparator arm, a finding that was statistically significant (p = 
0.016).  
In Chau et al.54, the percentage of subtherapeutic INRs (INR < 2.0) was 22.7% in the 
intervention arm and 33.2% in the comparator arm. The percentage of 
supratherapeutic INRs (INR > 3.0) was 9.4% in the intervention arm and 14.9% in the 
control arm. No patients had an INR above 6.0 in either arm.  
Damaske and Baird did not collect data on patients with subtherapeutic INRs.50 The 
percentage of patients with supratherapeutic INRs (any value above target range) 
was reported to be 17% for the intervention group (INR range 3.3 – 7.4 for five 
patients) and 27% for the comparator group (INR range 3.4 – 6.2 for six patients). 
The statistical significance of this result was not reported. 
In Schillig et al.52, the percentage of INRs above 5.0 was reported to be 9.6% in the 
intervention group and 14.8% in the comparator group, a finding that was not 
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Summary 
The five studies described above were all conducted in the inpatient setting with 
patients admitted under different treating units, including medical, respiratory, 
rehabilitation (following orthopedic intervention or stroke), cardiology and vascular 
units. In two studies,48,49 clinicians used a warfarin nomogram while only pharmacist 
prescribers had access to the nomogram in another.54 In the two remaining studies, it 
is unclear whether doctors had access to a nomogram in one,50 and it is not specified 
whether a nomogram was used in the remaining study.52  
In all five studies, the intervention arm performed better than the comparator arm but 
the statistical significance was not reported in three studies.48,50,54 In the remaining 
two studies, one showed statistical difference favoring the intervention arm,49 while 
the other did not show any statistical difference between groups.52 While none of 
these studies discuss the clinical significance of the findings, they indicate that 
pharmacists who prescribe warfarin according to a nomogram are able to maintain 
INR in therapeutic range just as well as doctors. These results are summarized in 
Table 10.        
3.4.4.3 Time to therapeutic range 
Four studies on anticoagulant prescribing reported time taken to achieve therapeutic 
range as an outcome measure. Of the four studies, one related to warfarin and 
heparin,42 two related to warfarin,50,54 and the other to heparin.51 One study was a 
randomized controlled trial,42 while the remaining three were quasi experimental 
studies.50,51,54 Due to the different anticoagulants studied and the heterogeneity of 
outcomes measured, no meta-analysis was performed. A narrative description of the 
studies follows. 
In Chenella et al.42, the mean number of days taken to achieve therapeutic 
proconvertin and prothrombin in inpatients who required continuous intravenous 
heparin and oral warfarin was 5.7 +/- 1.4 in the intervention group and 5.8 +/- 2.1 in 
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In Chau et al.54, mean time taken from commencement of warfarin therapy to first 
therapeutic INR was 2.8 days (range 0 – 10) in the intervention group and 3.0 days 
(range 0 – 14) in the comparator group. The significance of this finding was not 
reported but the difference in time reported to achieve target INR is not considered 
clinically relevant.  
Damaske and Baird reported the average time taken to achieve therapeutic INR from 
commencement of warfarin therapy.50 The average time taken was 6.0 days (range 4 
–11) in the intervention group and 5.6 days (range 4 –11) in the comparator group. 
The statistical significance of this finding was not reported but the difference in time 
reported to achieve target INR is not considered clinically relevant. 
For the two phases reported in the study by Pawloski et al.51: In Phase I, mean time 
(hours) to therapeutic APTT (activated partial thromboplastin time) was 16.52 +/- 
10.92 in the intervention arm and 46.5 +/- 34.13 in the comparator arm while in Phase 
II, this was reported to be 9.32 +/- 3.78 in the intervention arm and 31.64 +/- 32.74 in 
the comparator arm. In both phases, the difference in control and intervention arms 
was found to be statistically significant (p < 0.001). In both phases, there was no 
statistically significant difference in the mean number of days of heparin therapy per 
patient. 
Summary 
The four studies report varied results, with one finding that pharmacist prescribers 
achieved therapeutic range sooner when compared to doctors,51 another showing no 
difference between arms,42 and the remaining two studies not reporting statistical 
significance but reporting similar results across arms.50,54 These results indicate that 
when prescribing anticoagulants according to a dosing nomogram, pharmacists 
achieve therapeutic range around the same time as doctors. The clinical significance 
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Overall Summary – INR Control 
Pharmacists who prescribe warfarin according to a nomogram achieve therapeutic 
range within the same time period as doctors and maintain INR in therapeutic range 
just as well as doctors. 
3.4.5 Patient satisfaction 
Two randomized controlled trials included in the review reported patient satisfaction 
as an outcome measure.41,46 Due to heterogeneity in populations and the outcome 
measured, no meta-analysis was performed. The results are summarized in Table 11 
and a narrative description of the studies follows. 
 
Table 11: Patient Satisfaction Survey 
Study details  Survey details  Assessment  





USA), administered by a 
research assistant not 
blinded to patient 
allocation 
General satisfaction 
Intervention: 3.8 ± 0.5, p = 0.134 
Control: 4.0 ± 0.5 
 
Overall mean score (includes scores for technical 
quality, interpersonal manner, communication, 
financial aspect, time spent, accessibility) 
Intervention: 3.8 ± 0.2 
Control: 3.6 ± 0.3 




survey at the end of 
study  
Patients who responded to statement: “I am very 
satisfied with the pharmacy services that I receive” 
with “most of the time”  
(Data for sometimes, very rarely and never not 
reported in the study) 
Intervention: 88% 
Control: 68% 
p = 0.098 
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In the study by Chan et al.41, patients recruited in each arm were administered the 
patient satisfaction questionnaire (PSQ)-18 (RAND Corporation, USA) in an interview 
by a research assistant who was not blinded to patient allocation. When rating their 
general satisfaction, the intervention group scored a 3.8 +/- 0.5 and the control group 
scored a 4.0 +/- 0.5, which was not statistically significantly different (p = 0.134). 
Statistically significant differences between arms in favor of the pharmacist 
prescribing arm was found in terms of the amount of time spent with the clinician (p < 
0.001) and accessibility of the clinician (p < 0.001). There were no statistically 
significant differences between arms in terms of technical quality, interpersonal 
manner, communication and financial costs.  
In Vivian et al.46, patients were administered a patient satisfaction survey at baseline 
and at the end of the study. Patients were asked to respond to a variety of statements 
with either ‘most of the time’, ‘sometimes’, ‘very rarely’, or ‘never’. Patients responded 
to the statement ‘I am very satisfied with the pharmacy services that I receive’ with 
‘most of the time’ in 88% patients in the intervention group compared to 68% patients 
in the control group who only received traditional pharmacy services (medication 
dispensing and counselling). This finding was not statistically significant (p = 0.098). 
No significant changes were noted in either group from baseline to end of study. 
There was no statistically significant difference between arms for all other parameters 
measured except in the case of distractions in the clinic area which led to poor 
service. In this case, less distractions leading to poor service were found in the 
pharmacist prescribing arm (p < 0.018). 
Summary 
In two studies that reported on patient satisfaction, patients were found to be as 
satisfied with the care provided by pharmacist prescribers as with doctors. These 
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CHAPTER 4: DISCUSSION 
4.1 General Discussion 
Non-medical prescribing is well described in the literature, particularly in the field of 
nursing. However, published information on pharmacist prescribing is mainly limited 
to descriptions of the practice, barriers to implementation or perceptions of relevant 
stakeholders on pharmacist prescribing. Some systematic reviews have evaluated the 
impact of pharmacist prescribing, but included data from both the community and 
hospital setting, or presented results for combined data with other non-medical 
prescribers.14,23,24 A systematic review on the effects of pharmacist prescribing on 
patient outcomes in the hospital has not been previously undertaken and is important 
to inform health policy-makers on the safety and effectiveness of this intervention in 
easing the burden on the healthcare system.  
This review identified studies which assessed prescribing by protocol,41,42,46,48,49,50,51,54 
supplementary prescribing,39,44,45,53 and collaborative prescribing.43,47 
In the majority of studies, pharmacists used dosing nomograms to prescribe heparin 
or warfarin.  Prescribing by protocol is the least independent form of prescribing, 
where the pharmacist is required to prescribe initial and subsequent doses of 
medication based on a pre-existing guideline or dosing nomogram. This form of 
prescribing is non-complicated, and most pharmacists should be able to perform this 
task within their scope of practice, which may explain the large number of studies 
using this model of prescribing.41,42,48,49,50,51,52,54 It is also a natural extension of a 
pharmacist’s duty, which may make it more acceptable to doctors and hence easier to 
implement in a hospital setting. 
In studies trialing the supplementary prescribing model, pharmacists were not limited 
to the prescription of a particular type of medication.39,40,44,45,53 The studies were 
conducted among patients being admitted for elective surgery (i.e. in the 
preadmission clinic), in the ambulatory setting and in the inpatient setting. Three 
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USA, which likely reflects increasing interest of Australian pharmacist practitioners in 
expanding their scope of practice, given that pharmacist prescribing has not been 
legalized in Australia.  
Collaborative prescribing is the most autonomous model of prescribing, and well 
suited for the outpatient setting as there is invariably less interaction required 
between the doctor and pharmacist. The high level of autonomy required for 
collaborative prescribing means that pharmacist prescribers need to be specialized or 
trained in their area of practice, which also explains the small number of studies using 
this model of prescribing.43,47 
Regardless of the prescribing model used, all studies demonstrated that pharmacist 
prescribing is at least as safe as doctor prescribing. The strongest evidence was for 
supplementary prescribing of patients’ medications on admission to hospital where 
the quality was moderate. Two of the three included studies were randomized 
controlled trials;44,45 two trials had an independent panel who were blinded to 
participant allocation reviewing prescription errors using a medication 
appropriateness index.40,53 The medication appropriateness index standardizes the 
assessment of the quality of prescribing by making it less subjective and therefore 
more reliable.  
Of the 15 included studies, eight were conducted in the inpatient setting, five in 
outpatient clinics and two in preadmission clinics. Seven of the eight studies 
conducted in the inpatient setting were related to anticoagulant prescribing, six of 
which used the dependent prescribing model (one study did not provide adequate 
information to determine the prescribing model used).42,48,49,50,51,52,54 In the eighth 
study, the supplementary prescribing model was used and the pharmacist charted 
patients’ medications on admission in addition to performing VTE risk assessments.53 
In all cases, pharmacists were at least as good as doctors in medication 
management. The high number of studies conducted on anticoagulant prescribing in 
the inpatient setting may indicate that there is a higher acceptance by hospital 
clinicians of anticoagulant management by pharmacists, and that there may be less 
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conducted in the outpatient setting used various forms of pharmacist prescribing 
(dependent, supplementary and collaborative).41,43,44,46,47 Of these five studies, four 
related to management of chronic disease states (diabetes, hypertension and high 
cholesterol) and one related to anticoagulation management. Based on the type of 
conditions being managed in the outpatient setting, there is some suggestion that 
pharmacist prescribers may be effective in the management of chronic diseases (i.e. 
stable and non-acute disease states). The remaining two studies conducted in the 
preadmission clinic both utilized supplementary prescribing models and showed that 
compared to doctors, pharmacists prescribe patients’ existing medication therapy 
more accurately on admission.39,45 This provides some indication that pharmacist 
prescribers may be useful in the preadmission setting.    
A number of clinically significant outcomes were found in terms of prescribing errors. 
Pharmacist prescribers were found to be 21 and 31 times less likely than doctors to 
make prescribing errors in two studies respectively.39,53 Pharmacists were also found 
to make less errors per patient, and errors were identified in a smaller number of 
patients.53 In the same study, the proportion of patients with an error severity rating of 
moderate to high was 1.2% in the intervention group and 48.8% in the control group; 
no patients in the intervention group were assigned an extreme risk rating compared 
to 5.3% of patients in the control group. The difference in the number of patients 
assigned a moderate, high or extreme risk is of major clinical significance. 
Collectively, these severity categories of moderate, high or extreme are associated 
with increased length of stay or readmission, morbidity at discharge or death of the 
patient. In addition to the negative health impact on the patient, moderate, high or 
extreme errors are associated with an increased burden on the health care system 
financially. 
Prescribing errors are well documented in the literature and can be attributed to many 
factors including human error, lack of clinician knowledge or experience and system 
failure.33,34,59 In many countries, hospital-based prescribing is carried out mainly by 
junior doctors. Their training in diagnosis and multiple modalities of treatment and 
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practice, and may have little knowledge of usual recommended doses, drug 
interactions and adverse drug reactions, which can lead to an increased incidence of 
prescribing errors.60  
Pharmacists are trained in therapeutics and drug management for patients. By nature 
of the profession, they are exposed to a greater range of medications and have a 
broad knowledge of them. It is therefore not unexpected that pharmacists make less 
prescribing errors than doctors, especially when compared to junior doctors. The idea 
of pharmacists being part of a clinical team and acting as a defense against 
prescribing errors is not new. Studies have shown the benefits of pharmacist 
interventions in the hospital setting;61 if these benefits can also be shown with 
pharmacist prescribing, then the expansion of pharmacy services to include this 
service can be justified.  
The evidence in this review showed pharmacists were also found to have a 
statistically significantly lower rate of medication omissions compared to doctors; a 
finding also considered clinically significant.39,53 Hospital pharmacists have been 
described as more likely to exhibit behaviors in line with the trait of 
conscientiousness.62,63 People with this trait are usually more able to follow norms 
and rules (i.e. be more process driven) and have the ability to complete a task 
correctly. This, combined with their broader knowledge of medicines, may explain 
why pharmacists have been found less likely to omit patients’ medications on 
admission when compared to doctors. 
All other outcome measures examined in this review were assessed to have low 
quality of evidence. This included therapeutic failure or benefit (cardiovascular 
disease), adverse effects related to anticoagulant therapy, appropriateness of 
warfarin doses prescribed and effectiveness of anticoagulation prescribing. 
The evidence for cardiovascular benefit due to pharmacist prescribing was derived 
from randomized controlled trials but the level of evidence was downgraded mainly 
due to poor methodology (lack of allocation concealment or blinding) and small 
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effectiveness of therapy. Generally, biomarkers are used for a number of reasons. 
They are cheaper and easier to measure than the outcome of interest (e.g. blood 
pressure measurement versus morbidity and mortality from hypertension) and can be 
measured more quickly and earlier (e.g. cholesterol levels measured with a blood test 
versus collecting mortality data over several years).64  
The GRADE Handbook recommends that when surrogate endpoints are used, the 
level of evidence should be downgraded for indirectness.9 However, contrary to this 
recommendation, the level of evidence was not downgraded for the use of blood 
pressure, blood sugar control and cholesterol as surrogate endpoints for 
cardiovascular morbidity and mortality. There is good evidence to show that lowering 
of these biomarkers is associated with cardiovascular benefits, i.e. blood pressure 
reduction with antihypertensive medication(s) is associated with cardiovascular 
protection,65,66,67 blood sugar control reduces incidence and progression of 
microvascular complications (retinopathy, nephropathy, neuropathy) in both Type I 
and Type 2 diabetics,68,69 diabetic patients with hypertension have less microvascular 
and macrovascular complications when target blood pressure is less than 150/85 
mmHg,70,71 intensive blood sugar control significantly reduces coronary events,72,73,74 
and for every reduction of 1 mmol/L in LDL, there is a corresponding 22% reduction in 
cardiovascular morbidity and mortality.75 Studies have also shown that lowering LDL 
with statin therapy in patients with Type 2 diabetes leads to fewer cardiovascular 
events.76,77 
For the outcome of blood pressure management, a meaningful conclusion could only 
be drawn from one study due to failure to adjust for baseline differences in the 
remaining studies.  Hawkins et al.43 reported that pharmacists can manage blood 
pressure as well as doctors. There was no clinically significant differences between 
arms for blood pressure management in this study.   
For the outcome of diabetes control, the two studies that assessed this found a mean 
reduction in post-test blood sugar level or glycosylated hemoglobin (HbA1c) in the 
intervention arm, a finding that was clinically significant as any improvement in blood 
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diabetes.69 In one study, 35% of patients in the intervention group compared to 21% 
patients in the control group achieved HbA1c of 7% or less.44 An adequately powered 
study in this area should be a priority for future research because if found to be 
statistically significant, the effect size suggested by this study would be clinically 
significant as it equates to one extra patient achieving target HbA1c in the 
intervention group for every ten patients allocated to each prescribing group.  
For the outcome of cholesterol control, the only inference that could be made was 
that pharmacist prescribers can manage cholesterol as well as doctors. One study 
recruited small patient numbers (14 in total) and no meaningful conclusion could be 
drawn.47 In the remaining study, post-test mean LDL was found to be statistically 
significantly lower in the intervention group although this difference was not 
considered clinically significant.44 The percentage of patients who achieved a target 
LDL cholesterol of 2.6 mmol/L was also reported. However, this target was above the 
currently recommended target LDL of less than 1.8 mmol/L in patients with very high 
cardiovascular risk (i.e. type 2 diabetes), a target thought to provide the best benefit 
in terms of cardiovascular disease reduction.78 The study did not report the number of 
patients who achieved a reduction of at least 50% from baseline, which is also 
considered an acceptable target in patients at high risk of cardiovascular disease who 
fail to achieve target LDL of below 1.8 mmol/L.78   
Adverse events were measured in studies which involved anticoagulant (heparin 
sodium and warfarin) prescribing and related to bleeding or thromboembolic 
events.41,42,49,50,52,54 The quality of evidence for this outcome measure was assessed 
to be low. While the number of adverse events that occurred in each arm was similar, 
a meaningful conclusion could not be drawn from these results for a number of 
reasons. Randomized controlled trials or prospectively controlled quasi experimental 
trials are not usually designed to detect adverse outcomes.79,80 This is mainly due to 
the nature of the trial design, where the adverse outcome may be poorly defined or 
not the main outcome of interest, there is limited statistical power to detect rare 
events that occur, and the duration of the study may not be sufficiently long enough to 
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conducted to measure efficacy of the intervention, these studies were underpowered 
to detect the difference in adverse events between groups. This was further 
compounded by the small number of events that occurred in each arm. Where 
classification of bleeding events occurred (minor, major, life-threatening), they differed 
between studies, making comparison across studies difficult.  
For the outcome of appropriate warfarin doses prescribed, the quality of evidence 
was graded as low. The studies included quasi experimental trials which carry a risk 
of allocation bias; participants or those delivering treatment were not blinded; and 
included a small number of participants. Pharmacists were found to comply with 
warfarin guidelines fully (100%), while doctors were found to comply with the 
guidelines approximately 70% of the time when initiating loading doses and 46% of 
the time when initiating maintenance doses.49,50 The finding that pharmacists are 
better at adhering to guidelines is not surprising, as pharmacists who are authorized 
to prescribe by protocol can only legally prescribe according to those guidelines. In 
addition, the pharmacist prescribers in this study were aware that their prescribing 
was being assessed for appropriateness.  Doctors had access to dosing guidelines in 
both studies but were not obliged to use them in at least one of these studies, while 
guidelines were used by pharmacists in both studies (although one study allowed 
deviation from guidelines according to the clinical judgement of the pharmacist). 
Warfarin nomograms are designed to guide initiation of warfarin therapy but the 
optimal warfarin dosing regimen has not been firmly established.81,82 In some cases, 
a doctor’s clinical judgement and experience may be just as effective as warfarin 
nomograms and hence assessing adherence to these guidelines may not be a good 
indication of whether INR will be achieved in a desired timeframe. 
The studies in this review showed pharmacists were better than doctors at assessing 
and prescribing venous thromboembolism prophylaxis in the preadmission clinic.39 
However, this benefit was not apparent when medication charts were assessed on 
admission, suggesting that prescriptions written by doctors in the preadmission clinic 
are usually re-assessed, with most errors corrected appropriately at the time of 
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under when patients are being assessed in the preadmission clinic, with less care 
being taken for prescribing when the medication chart is not expected to be in use 
until the patient’s admission to hospital, which may be weeks after the time of 
prescribing.  
For the outcome of effectiveness of anticoagulation prescribing (i.e. maintenance of 
INR in therapeutic range), the evidence was graded as low. The studies included 
quasi experimental trials which carry a risk of allocation bias and included a small 
number of participants. International Normalized Ratio was used as a surrogate 
endpoint for therapeutic effectiveness but the level of evidence was not downgraded 
as recommended by the GRADE Handbook.9 This is because there is good evidence 
to show that INR is correlated with therapeutic effect, bleeding and thromboembolic 
risk. The optimum therapeutic range for most conditions requiring anticoagulation is 
well established to be an INR between 2.0 and 3.0. Patients with better INR control 
are less likely to have bleeding and thromboembolic events.83 The incidence for major 
bleeding when INR is greater than 3.0 is doubled compared to when INR is between 
2.0 and 3.0.83 Bleeding rate as a whole doubles as the INR increases from 2.0 – 2.9 
to 3.0 – 4.4, quadruples between 4.5 – 6.0 and multiplies by five when INR is above 
7.0, with a consistent increase in major bleeding when INR exceeds 4.0 – 5.5.84  
Previous research indicates that in patients with poor INR control (time in therapeutic 
range less than 60%), major bleeding and mortality rate is 3.85% and 4.20% 
respectively, compared to 1.96% and 1.84% in patients with moderate INR control 
(time in therapeutic range between 60 – 70%), and 1.58% and 1.69% in patients with 
good INR control (time in therapeutic range greater than 75%).85 
International Normalized Ratio as a surrogate endpoint becomes an important 
measure when bleeding or thromboembolic events are rare and are less useful in 
studies that are performed short term or recruit small patient numbers.  
Thromboembolic events can transpire as the result of failure to anticoagulate patients 
at risk, or to provide inadequate anticoagulation in patients with established risk 




P a g e  | 76 
to achieve target values for laboratory markers known to reduce thromboembolic risk, 
e.g. INR for warfarin and Activated Partial Thromboplastin Time (APTT) for heparin. 
International Normalized Ratio is considered sub-therapeutic when the value is below 
2.0, but studies have shown that the risk of thromboembolism rises most acutely 
when INR is 1.5 or below.86,87 Inadequate anticoagulation has been shown to predict 
higher rates of recurrence of venous thromboembolism.87   
Overall, the results of the studies assessed in this review indicated a clinically 
significant difference between pharmacist and doctor prescribing with a reduced 
bleeding risk in the pharmacist arm. The key findings from the studies included: 
• more time spent in therapeutic range (64% versus 59%), corresponding to an 
absolute risk reduction for major bleeding and mortality of 1.89% and 2.36% 
respectively in the intervention group based on moderate INR control in the 
intervention group compared to poor INR control in the control group.41  
• less patients with an INR above 6.0 (1% versus 5%) in the intervention arm, 
where an INR above 6.0 confers a four times increase in bleeding risk 
compared to an INR between 2.0 – 3.0.48   
In terms of thromboembolic risk, the main conclusion that can be made is that 
patients in the intervention arm were at lower risk of thromboembolic events. No 
inference can be made on whether these findings were clinically significant without 
further information on the range of INR values measured below 2.0.    
No studies showed clinically significant differences between arms for the time it took 
to reach therapeutic range.  
In general, pharmacist prescribing was considered appropriate by doctors where this 
was assessed, as judged by their high agreement with therapeutic plans made by 
pharmacist prescribers. Caution needs to be used in interpreting this finding as the 
studies used doctor judgement as the gold standard rather than pre-determined 
criteria or accepted standards of practice.  
Overall, satisfaction surveys conducted indicate that patients are as satisfied with 
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that patients perceived pharmacists to be more accessible and spent more time with 
them during their appointment. This is reflective of general consensus that 
pharmacists are one of the most accessible health care professionals to the general 
public.88 While these initial results on satisfaction related to the services provided are 
promising, the two studies included were conducted more than ten years ago. During 
this time, there have been significant changes in the clinical services provided by 
hospital pharmacists,89,90 and more up-to-date studies on patient satisfaction with 
pharmacist prescribing are warranted to reflect current viewpoints.   
4.2 Benefits of pharmacist prescribing 
The main benefit of non-medical prescribing is associated with the resultant flexible 
model of care that can be provided to patients, and increased workforce flexibility. 
This can improve patients’ accessibility to healthcare practitioners and medications in 
addition to reducing waiting times. Patients would also have the choice of consulting a 
healthcare professional (either doctor or pharmacist) they have formed a relationship 
with. In the case of the pharmacist, there is the additional advantage of expertise in 
medicines, including knowledge on drug interactions, adverse drug reactions and 
other medication related issues. The pharmacist can also potentially provide more in-
depth medication counselling to the patient at the time of prescribing. The 
corresponding reduced workload of doctors may also minimize errors that occur due 
to high workload demands on doctors and their other competing priorities.  
Pharmacist prescribing may also be beneficial in specialized areas of practice such 
as cardiology, particularly in anticoagulation or hypertension clinics as demonstrated 
in the studies included in this review. In these studies, pharmacists were running the 
clinics independently using medication protocols to guide prescribing. Specializing in 
an area of practice ensures that the pharmacist has a comprehensive knowledge of 
medical conditions, medications and monitoring requirements for patients seen in that 
clinic. Doctors are then able to use their time to assess and treat patients with more 
complex disease states. This model of care could also potentially be used in other 
specialized areas of practice such as endocrinology, emergency medicine, 
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Pharmacist prescribing may also improve the workflow and efficiency of a patient’s 
hospital journey. For example, medication histories for patients are often taken more 
than once during their admission to hospital, firstly when being assessed by a doctor 
in the emergency department, then possibly by a doctor in the admitting unit, and at 
some stage during hospitalization by a clinical pharmacist. This process can be 
simplified by having a clinical pharmacist perform a medication history for the patient 
on admission, and pharmacists prescribing the required medications on a medication 
chart. This would also negate the need for hospital doctors to prescribe the patient’s 
usual medications prior to admission. Any issues arising regarding medications which 
may need to be held or ceased on admission can be discussed with the patient’s 
doctor, reducing the potential for inadvertent administration of medications which are 
no longer required.  
This review provides low to moderate evidence that pharmacists are able to prescribe 
to the same standards as doctors, and when prescribing by protocol, pharmacists are 
in fact better at adhering to dosing guidelines and make less prescribing errors in 
terms of charting patients’ usual medications on admission to hospital. At least one 
study also found that pharmacist prescribing was associated with reduced costs in an 
anticoagulation outpatient clinic, although this was mainly due to the differences in 
salaries between pharmacists and doctors.41  
When considering implementation of pharmacist prescribing in hospitals, prescribing 
by protocol (e.g. warfarin dosing) should be considered first, as this requires less 
training and expertise compared to other forms of prescribing. Other forms of 
dependent prescribing could then be considered subsequently for implementation. 
Collaborative and independent prescribing requires more autonomy especially if it is 
not restricted to specific medication classes and therefore should be considered in 
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4.3 Barriers to implementation of pharmacist prescr ibing 
The perceived barriers to the successful implementation of pharmacist prescribing are 
well documented in the literature and are mainly related to supplementary, 
collaborative or independent prescribing models. 91,92,93,94,95,96,97 
Patient views on pharmacist prescribing have been generally positive, although 
patients indicated that they would prefer the doctor to make the initial diagnosis, and 
for a multidisciplinary team approach to be used in cases involving complex medical 
conditions.91,92,95 
Doctors have identified the following issues as potential barriers to pharmacist 
prescribing – feeling that their [doctor] authority is being infringed, pharmacists’ 
awareness [or lack thereof] of clinical and patient details, pharmacists’ lack of clinical 
examination skills, potential communication problems, belief that a doctor should write 
the initial inpatient prescription and the loss of opportunity to review drug 
treatment.93,94,95 
Pharmacists have also identified barriers towards implementation of pharmacist 
prescribing. Further training (e.g. clinical examination skills, medico-legal aspects) 
was felt to be required for this additional responsibility, in addition to adequate 
experience prior to taking on this role, and concerns with the potential extra demands 
on their time.96,97 In 2007, pharmacist prescribing was legalized in Alberta, Canada 
through the Health Professions Act Standards for Pharmacist Practice to allow the 
modification of prescriptions or prescribing for an emergency encounter.98,99  For 
additional prescribing rights, pharmacists had to successfully apply for additional 
prescribing authorization. At the end of the year 2013, 435 pharmacists, equivalent to 
less than 10% of registered practitioners, had applied and been granted additional 
prescribing authorization.100 As a result of this finding, recommendations were made 
by the Alberta Health Services to try and overcome some of the perceived barriers, 
identified through pharmacist interviews, observation of practice and other 
documentation, in adopting this change of practice. These recommendations included 
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ongoing skill development through continuing professional programs, recognition and 
incentives for prescribing pharmacists (e.g. educational funding or increased clinical 
contact time) and helping pharmacists to establish their prescribing role within their 
practices.100 
To ensure that the model of pharmacist prescribing remains robust and viable, a 
multitude of factors need to be addressed. While the concerns identified by patients, 
doctors and pharmacists discussed above are all valid, they are related to pharmacist 
prescribers and those they affect directly through their practice. Other overarching 
issues which also need to be addressed include legislative change, workforce 
capacity, and access to medical records. The lack of a coordinated international 
approach in legalizing pharmacist prescribing is one of the major barriers in 
implementing pharmacist prescribing. This is exacerbated by the lack of uniform 
policy, even within the same country. For example, Canadian pharmacists have 
different prescribing rights (or no rights) depending on the province in which they 
practice.101,102 At a national level, legislative changes required to allow pharmacist 
prescribing is the major barrier to its implementation. Professional bodies for 
pharmacists will need to work together to drive this change as it is unlikely to come 
from any other organization. This may have been a challenge in the past given the 
previous lack of good quality evidence which would prevent policy makers from 
endorsing the change in practice. The professional registration body for pharmacists 
will also need to ensure that there are regulations which will govern safe practice, 
including recognition of prescribing competency, compulsory accredited education 
and training, ensuring pharmacists prescribe within their scope of practice, as well as 
ensuring pharmacists maintain their competency to prescribe.10 The workforce 
capacity will also determine the adoption of this new practice, especially if the 
additional prescribing role will reduce the time available for other more traditional 
clinical duties. Access to medical records present an interesting challenge, especially 
in institutions that do not have access to electronic records. Safe prescribing cannot 
take place if the pharmacist is unable to access a patient’s medical history or view 
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practitioner. In these cases, the pharmacist would be reliant entirely on effective 
communication with the doctor and patient.  
4.4 Limitations of the studies 
The studies included in this review were conducted in different settings – inpatients, 
outpatients and preadmission clinics. Each hospital setting is associated with different 
pharmacy prescribing foci. For example, outpatient clinics usually cater for patients 
with a specific medical condition such as hypertension or patients on warfarin which 
limits the prescribing activities of a pharmacist, while prescribing activities in a 
preadmission clinic are usually related to medications patients were taking prior to 
admission and consideration of venous thromboembolism prophylaxis. When 
considering the applicability of the findings in this review in clinical practice, both the 
specific outcome and the hospital setting the study was conducted in should be taken 
into account.  
In addition to only a limited number of studies of high quality being identified, a high 
proportion of the studies only recruited small numbers of patients. Caution needs to 
be used when considering the clinical significance of the results due to small patient 
numbers.  
In a number of studies, the methodology of the study was poorly reported or lacking in 
detail. In others, statistical analysis was either not made or the method used was not 
specified. The majority of studies did not report power and sample size analyses and 
studies which found no difference between arms may have lacked power to detect 
statistically significant differences. The lack of transparency in the reporting of these 
issues is a concern as there is a risk the studies were not well designed and prone to 
bias. Another bias that requires consideration is that most of the studies were 
designed by a pharmacist, with data collection and data analysis performed by the 
same pharmacist. There is a risk that the study design was biased towards a positive 
finding, and that negative findings were not reported. For example, in one study, 
patients in the intervention arm had their medication history taken in the preadmission 
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discharge, possibly resulting in a recall bias by patients and a distortion of the results 
of the study.45  
There was also significant heterogeneity in the outcome measures that were reported 
between studies. For example, when reporting on INR control, the studies reported on 
patient time or percentage of INRs or patients in a specified range. In cases where 
the outcome measure was consistent across studies, there was variation in the 
definition of the outcome measure. For example, where bleeding was reported as an 
adverse event, it was further subdivided into major or minor bleeding in some studies, 
but different definitions were used for these events. These differences in reporting 
meant that data pooling in a meta-analysis was not possible.  
Studies that reported on therapeutic failure or benefit as an outcome measure did not 
account for differences in baseline measures between arms,43,44,46 while other studies 
did not adjust for patient mix.39,43,46 Of the three studies which had statistically 
significant differences between mean baseline measures between groups, only one 
study adjusted for this difference using an analysis of covariance (ANCOVA).43 Due to 
the potential for over- or under-estimation of the intervention effect when there is a 
difference in baseline measures between groups, ANCOVA has been recommended 
as the preferred statistical analysis for trials with baseline and follow up 
measurement.56 In a simulation study, ANCOVA has been found to have generally 
greater statistical power to detect a treatment effect compared to other methods.103 
The failure to account for the difference in study population between arms makes it 
difficult to interpret the study findings and consequently no definitive conclusions 
could be made.  
Although statistical significance was reported for some studies, a more relevant 
measure of effectiveness, the clinical significance of the findings, was not discussed 
in any of the included studies. Studies with large sample sizes may report a 
statistically significant difference between groups which are not clinically important.  
Other limitations were also present in the studies included in the review. This included 
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pharmacists versus junior doctors), and the definition of what was considered 
appropriate prescribing. Medications were considered to be prescribed appropriately 
if they could be reconciled with the patient’s medication list prior to admission. 
However, this does not necessarily constitute appropriate prescribing if medications 
that are no longer appropriate for the patient (due to factors such as change in a 
patient’s disease state or organ function) are not reviewed and continue to be 
prescribed. 
4.5 Limitations of the review 
This review aimed to include studies performed in the hospital setting but this proved 
to be more challenging than originally anticipated.  In the United States of America, 
the health care system is unique in that it is provided by various organizations such 
as the government, health insurance providers and not-for-profit establishments. 
Health care in the USA is provided in settings ranging from hospitals, health 
maintenance organizations, medical centers, Veterans Affairs Medical Centers 
(VAMC) and university affiliated outpatient clinics. The distinction between a specialist 
medical center with the capacity to admit patients and a hospital in the traditional 
sense was not straightforward. This review included all papers which specifically 
stated the studies were conducted in a hospital setting. Where a hospital setting was 
not specified, studies were included if they met the definition of a hospital according 
to the World Health Organization; i.e. “Hospitals are health care institutions that have 
an organized medical and other professional staff, and inpatient facilities, and deliver 
services 24 hours per day, 7 days per week. They offer a varying range of acute, 
convalescent and terminal care using diagnostic and curative services”.104(para.1) 
Studies that were performed in outpatient clinics but did not specifically state their 
affiliation to a hospital were excluded. Based on these criteria, studies may be 
considered to have been included or excluded inappropriately by persons more 
familiar with the nomenclature used in the description of health care settings in the 
USA.      
A systematic search was conducted across multiple databases (including one for gray 
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possible that some articles were missed in this process. The largest limitation in the 
search methodology was the lack of medical subject heading for ‘pharmacist 
prescribing’, which led to a need to search for the two keywords separately. This 
resulted in retrieval of a large number of articles which required screening to 
determine inclusion or exclusion in this review. The large volume of articles, which 
was screened by a sole reviewer, increased the possibility that relevant studies were 
not identified and omitted from this review. While two reviewers critically appraised 
the studies identified for inclusion, only one reviewer performed data extraction, 
increasing the risk for errors. In addition, only studies in English were considered for 
inclusion, introducing a language bias in this review.  
The high level of heterogeneity between the studies included in the review meant that 
statistical pooling of data in a meta-analysis was not possible. Consequently, only a 
general statement that pharmacist prescribing has been shown to be just as effective 
as doctors can be made.  
It should also be highlighted that prescribing is often not the sole activity that is being 
performed by the pharmacist or doctor, with pharmacists performing inherently 
different activities to doctors. For example, prior to prescribing a pharmacist may be 
more focused on medication history-taking, medication reconciliation and medication 
review, while a doctor may be more concerned with medical examination and clinical 
diagnosis. Additionally, pharmacists are more likely to provide patients with 
medication counselling when writing a prescription. These additional activities cannot 
be separated from the act of prescribing for each of the professions and their effects 
on prescribing outcomes have not been accounted for in this review. Similarly, in 
some studies in this review, there may have been slight variations in the intervention 
studied. For example, a different duration between follow-up appointments in the two 
groups or patients offered additional lifestyle modification advice in one arm. These 
differences could have influenced the study outcomes.     
All the studies measuring therapeutic failure or benefit as an outcome used surrogate 
endpoints as the measure of effectiveness of therapy. Surrogate endpoints used in 
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cholesterol (low density lipoprotein and total cholesterol), blood sugar levels and 
glycosylated hemoglobin. The level of evidence was not downgraded for indirectness 
in this review as improvement in these endpoints are well established to be correlated 
with reduction of cardiovascular events including stroke, myocardial infarction and 
mortality. While this was considered appropriate for this review, it may also be 
considered a limitation as it is in contradiction to the recommendations made in the 
GRADE approach.9   
The clinical significance of the findings were discussed in the review and derived from 
primary literature where possible. However, as clinical judgement (which is 
subjective) is required to determine whether an intervention is clinically significant, 
other stakeholders may have differing views on whether the findings of a study is 
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CHAPTER 5: CONCLUSION 
5.1 Conclusion 
Overall, the studies included in this review indicate that pharmacist prescribing is non-
inferior to doctor prescribing in all measured outcomes of interest. This included the 
prescription of medications to manage blood pressure, diabetes and cholesterol; the 
prescription of heparin sodium and warfarin according to dosing nomograms; and the 
prescription of patients’ usual medications on admission to hospital. Pharmacists 
performed better than doctors in several aspects of prescribing, specifically in the 
accuracy of prescribing a patient’s usual medication regime on admission and in 
adhering to dosing nomograms. 
5.2 Implications for practice  
Pharmacists are less likely than doctors to make prescribing errors or omit 
medications from the medication chart when prescribing medications for patients on 
admission to hospital. Based on the results of this review, it is recommended that as 
part of their scope of practice hospital pharmacists prescribe a patient’s existing 
medications during the patient’s initial presentation to hospital (including in the 
preadmission clinic), conditional upon the use of the supplementary prescribing model 
(Grade B). Pharmacists are non-inferior to doctors when prescribing medications to 
reduce the risk of cardiovascular disease, particularly in the management of 
hypertension, diabetes and cholesterol. It is recommended that hospital pharmacists 
prescribe medications for the management of blood pressure, diabetes or cholesterol 
in hospital outpatient clinics, conditional upon this prescribing being consistent with 
dependent or collaborative prescribing models (Grade B). When prescribing 
anticoagulants according to protocol, the evidence shows pharmacists maintain 
International Normalized Ratio in therapeutic range just as well as doctors; this is also 
reflected in the similar number of adverse events between arms. The evidence also 
shows pharmacists prescribe warfarin doses according to warfarin nomograms more 
accurately than doctors. It is recommended that hospital pharmacists prescribe 
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outpatient setting, conditional upon this prescribing being in accord with dosing 
nomograms (Grade B).105 
5.3 Implications for research  
This review did not identify any studies which used an independent prescribing 
model. Future research should consider the effectiveness of pharmacist prescribing 
with this more autonomous model of prescribing as it may be beneficial in some areas 
of practice, such as in remote areas with less access to medical care. No studies 
were found assessing pharmacist prescribing in children or adolescents (below 18 
years of age). Future research should also include this age group in the study design. 
There was a lack of studies focusing on specific clinical areas such as mental health, 
respiratory conditions, infectious diseases and obstetrics; future research should 
consider these clinical domains.      
This review further highlighted a lack of research in pharmacist prescribing with a 
specific focus on clinical outcomes such as morbidity, mortality and adverse events. 
Studies that reported mortality and adverse events as secondary outcomes were 
insufficiently powered to detect a clinically important difference between arms. Future 
research should include adequately powered, rigorously conducted and 
methodologically sound randomized controlled trials that address this research gap. 
Surrogate endpoints such as blood pressure and cholesterol control remain important 
measures of effectiveness of the intervention but should be measured in conjunction 
with clinical outcomes of interest such as morbidity, mortality, hospital admissions and 
cardiovascular events. While this review did not consider health care cost as a 
patient-related outcome, it highlighted a lack of methodologically sound studies which 
included economic assessments. Future research should consider comparing health 
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APPENDIX I – SEARCH STRATEGY  
 
PubMed  
• search strategy executed on 24/1/17 
No. Search terms  No. 
Results 
1 Pharmacists[mh] OR pharmacist*[tw] OR clinical pharmacy[tw] 29,701 
2 Pharmaceutical services[mh] OR pharmaceutical service*[tw] OR pharmacy 
service*[tw] OR pharmaceutical care*[tw] OR pharmacy service, hospital[mh] 
OR pharmacy[mh] OR pharmacy[tw] OR hospital pharmacy[tw] 
93,392 
3 Drug prescriptions[mh] OR prescription*[tw] OR prescribe*[tw] OR 
prescribing*[tw] 
177,968 
4 Hospitals[mh] OR hospital*[tw] OR secondary care[tw] OR secondary health 
care[tw] OR tertiary care[tw] OR tertiary health care[tw] OR outpatients[mh] OR 
outpatient*[tw] OR ambulatory care[mh] OR ambulatory care facilities[mh] OR 
ambulatory care[tw] OR ambulatory service[tw] OR emergency service, 
hospital[mh] OR emergency service*[tw] OR emergency department*[tw] or 
emergency room[tw] OR emergency ward*[tw] OR emergency unit*[tw] or 
accident and emergenc*[tw] OR perioperative period[mh] OR perioperative[tw] 
OR perioperative care[mh] OR intraoperative[tw] OR preoperative[tw] OR 
elective surgical procedures[mh] or elective surg*[tw] 
1,894,359 
5 (#1 or #2) AND #3 AND #4 10,968 
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Embase 
• search strategy executed on 24/1/17 
No. Search terms  No. 
Results 
1 Pharmacist:de OR pharmacist*:ti,ab OR ‘clinical pharmacy’:de OR ‘clinical 
pharmacy’:ti,ab 
84,682 
2 ‘hospital pharmacy’:de OR ‘hospital pharmacy’:ti,ab OR ‘hospital pharmacy 
service’:ti,ab OR pharmacy:de OR pharmacy:ti,ab OR ‘pharmaceutical 
service’:ti,ab OR ‘pharmaceutical services’:ti,ab OR ‘pharmacy service’:ti,ab OR 
‘pharmacy services’:ti,ab OR ‘pharmaceutical care’:ti,ab 
110,537 
3 Prescription:de OR prescription*:ti,ab OR prescribing:ti,ab OR prescribe*:ti,ab 306,207 
4 Hospital/exp OR hospital*:ti,ab OR ‘secondary health care’/exp OR ‘secondary 
care’:ti,ab OR ‘secondary health care’:ti,ab OR ‘tertiary health care’/exp OR 
‘tertiary health care’:ti,ab OR ‘tertiary care’:ti,ab OR outpatient:de OR 
outpatient*:ti,ab OR ‘ambulatory care’/exp OR ‘ambulatory care’:ti,ab OR 
‘ambulatory service’:ti,ab OR ‘emergency health service’:de OR ‘emergency 
service’:ti,ab OR ‘emergency services’:ti,ab OR ‘emergency department’:ti,ab 
OR ‘emergency room’:ti,ab OR ‘emergency ward’:ti,ab OR ‘emergency unit’:ti,ab 
OR ‘accident and emergency’:ti,ab OR ‘accident and emergencies’:ti,ab OR 
‘perioperative period’:de OR perioperative:ti,ab OR intraoperative:ti,ab OR 
preoperative:ti,ab OR ‘elective surgery’:de OR ‘elective surgery’:ti,ab OR 
‘elective surgeries’:ti,ab  
2,459,708 
5 #1 or #2 151,837 
6 #3 AND #4 AND #5 13,826 
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CINAHL 
• search strategy executed on 24/1/17 
No. Search terms  No. Results  
1 MH pharmacists OR TI pharmacist* OR AB pharmacist* OR TI ‘clinical 
pharmacy’ OR AB ‘clinical pharmacy’  
9,108 
2 MH pharmacy service+ OR TI ‘hospital pharmacy’ OR AB ‘hospital pharmacy’ 
OR TI ‘hospital pharmacy service’ OR AB ‘hospital pharmacy service’ OR TI 
pharmacy OR AB pharmacy OR TI ‘pharmaceutical service*’ OR AB 
‘pharmaceutical service*’ OR TI ‘pharmaceutical care’ OR AB ‘pharmaceutical 
care’ 
10,602 
3 MH medication prescribing OR TI prescribing OR AB prescribing OR TI 
prescribe* OR AB prescribe* OR MH prescriptions, drug OR TI prescription* OR 
AB prescription* OR MH prescriptions, non-drug 
38,662 
4 MH hospitals+ OR TI hospital* OR AB hospital* OR MH secondary health care 
OR TI ‘secondary health care’ OR AB ‘secondary health care’ OR TI ‘secondary 
care’ OR AB ‘secondary care’ OR MH tertiary health care OR TI ‘tertiary health 
care’ OR AB ‘tertiary health care’ OR TI ‘tertiary care’ OR AB ‘tertiary care’ OR 
MH outpatient service OR TI outpatient* OR AB outpatient* OR MH outpatients 
OR MH ambulatory care facilities+ OR TI ‘ambulatory care’ OR AB ‘ambulatory 
care’ OR TI ‘ambulatory service’ OR AB ‘ambulatory service’ OR MH emergency 
service+ OR TI ‘emergency service*’ OR AB ‘emergency service*’ OR TI 
‘emergency department’ OR AB ‘emergency department OR TI ‘emergency 
room’ OR AB ‘emergency room’ OR TI ‘emergency ward’ OR AB ‘emergency 
ward’ OR TI ‘emergency unit’ OR AB ‘emergency unit’ OR TI ‘accident and 
emergenc*’ OR AB ‘accident and emergenc*’ OR MH perioperative care+ OR 
MH preoperative period+ OR TI perioperative OR AN perioperative OR TI 
intraoperative OR AB intraoperative OR TI preoperative OR AB preoperative OR 
MH surgery, elective+ OR TI ‘elective surger*’ OR AB ‘elective surger*’ 
362,825 
5 #1 OR #2 16,105 
6 #3 AND #4 AND #5 1,139 
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Cochrane Central Register of Controlled Trials 
• search strategy executed on 24/1/17  
• searched in title, abstract or as keywords 
No. Search terms  No. 
Results 
1 Pharmacist OR “clinical pharmacy” 3,927 
2 “pharmacy service” OR “hospital pharmacy” OR “hospital pharmacy service” OR 
pharmacy OR “pharmaceutical service” OR “pharmaceutical care” 
11,586 
3 “medication prescribing” OR prescribing OR prescribe* OR “drug prescription” 
OR prescription* 
19,749 
4 Hospital* OR “secondary health care” OR “secondary care” OR “tertiary health 
care” OR “tertiary care” OR “outpatient service” OR outpatient* OR “ambulatory 
care facilities” OR “ambulatory care” OR “ambulatory service” OR “emergency 
service” OR “emergency department” OR “emergency room” OR “emergency 
ward” OR “emergency unit” OR “accident and emergency” OR “perioperative 
care” OR “preoperative period” OR perioperative OR intraoperative OR “elective 
surgery”   
252,227 
5 #1 OR #2 12,729 
6 #3 AND #4 AND #5 1,808 
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Scopus 
• search strategy executed on 24/1/17 
No. Search terms  No. 
Results 
1 Pharmacist OR “clinical pharmacy” 76,396 
2 “Pharmacy service*” OR “hospital pharmacy” OR “hospital pharmacy service” 
OR pharmacy OR “pharmaceutical service*” OR “pharmaceutical care” 
123,586 
3 “Medication prescribing” OR prescribing OR prescribe* OR “drug prescription” 
OR prescription 
348,811 
4 Hospital* OR “secondary health care” OR “secondary care” OR “tertiary health 
care” OR “tertiary care” OR “outpatient service*” OR outpatient* OR “ambulatory 
care facilit*” OR “ambulatory care” OR “ambulatory service*” OR “emergency 
service*” OR “emergency department” OR “emergency room” OR “emergency 
ward” OR “emergency unit” OR “accident and emergency” OR “perioperative 
care” OR “preoperative period” OR perioperative OR intraoperative OR “elective 
surger*”   
2,274,309 
5 #1 OR #2 158,029 
6 #3 AND #4 AND #5 11,647 
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Web of Science Core Collection 
• search strategy executed on 24/1/17 
No. Search terms  No. 
Results 
1 pharmacist OR “clinical pharmacy”  * 
2 “Pharmacy service*” OR “hospital pharmacy” OR “hospital pharmacy service” 
OR pharmacy OR “pharmaceutical service*” OR “pharmaceutical care” 
* 
3 “Medication prescribing” OR prescribing OR prescribe* OR “drug prescription” 
OR prescription 
* 
4 Hospital* OR “secondary health care” OR “secondary care” OR “tertiary health 
care” OR “tertiary care” OR “outpatient service*” OR outpatient* OR “ambulatory 
care facilit*” OR “ambulatory care” OR “ambulatory service*” OR “emergency 
service*” OR “emergency department” OR “emergency room” OR “emergency 
ward” OR “emergency unit” OR “accident and emergency” OR “perioperative 
care” OR “preoperative period” OR perioperative OR intraoperative OR “elective 
surger*”   
* 
5 (#1 OR #2) AND #3 AND #4  * 
6 Limit #5 to English 6,978 
* Exact number not available – database only offers approximately numbers until duplicates are removed when the 
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Mednar 
• search strategy executed on 24/1/17: 
No. Search terms  No. 
Results 




• search strategy executed on 24/1/17 
No. Search terms  No. 
Results 
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APPENDIX II – EXCLUDED STUDIES 
Abutaleb MHA. Clinical comparative effectiveness of independent non-medical prescribers for type 2 
diabetes. 2015.  
Reason for exclusion: Not a controlled study - obse rvational, retrospective design 
Adams GW. Parenteral nutrition collaborative drug therapy management service. Hosp Pharm. 
2000;35(11):1242–8.  
Reason for exclusion: Not a study - narrative only 
Albsoul-Younes AM HE Yasein NA, Tahaineh LM. Pharmacist-physician collaboration improves blood 
pressure control. Saudi Med J. 2011;32(3):288–92.  
Reason for exclusion: Does not involve pharmacist p rescribing 
Baqir W CJ Smith J. Evaluating pharmacist prescribing across the North East of England. Br J Clin 
Pharm. 2010;2:147–9.  
Reason for exclusion: Not a controlled study - obse rvational 
Bhanji AA FK LeBlanc SP. Pharmacy involvement in a surgery preadmission program. Am J Hosp Pharm. 
1993;50(3):483–6.  
Reason for exclusion: Not pharmacist prescribing 
Bunz D GS Jewesson P. Metronidazole cost containment: a two-stage intervention. Hosp Formul. 
1990;25(11):1167–9, 1177.  
Reason for exclusion: Not considered pharmacist pre scribing - changing dosing interval from 8 
hourly to 12 hourly using pre-stamped form; Pre-tes t post-test study 
Cao BY CC Elliott P, MacPherson RD, Crane J, Bajorek BV. Implementing a Pharmacist Charting Service 
in the PreAdmission Clinic. J Pharm Pract Res. 2011;41(2):102–7.  
Reason for exclusion: Not a controlled study - Pre- test post-test study 
Cattell R CC Sheikh A. Pharmacist integration into the discharge process: A qualitative and quantitative 
impact assessment. Int J Pharm Pract. 2001;9(1):59–64.  
Reason for exclusion: Not pharmacist prescribing - transcribing only 
Chantelois EP SN. A pilot program comparing physician- and pharmacist-ordered discharge medications 
at a Veterans Affairs Medical Center. Am J Health Syst Pharm. 2003;60(16):1652–6.  
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Chiquette E AM Bussey HI. Comparison of an anticoagulation clinic with usual medical care: 
anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641–7.  
Reason for exclusion: Not hospital setting 
Clifford RM BK Davis TME, Davis W, Stein G, Stewart G, Plumridge RJ. A randomised controlled trial of a 
pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract. 
2002;10(2):85–9.  
Reason for exclusion: Not pharmacist prescribing 
Choe HM KJ Choi KE, Mueller BA. Implementation of the first pharmacist-managed ambulatory care 
anticoagulation clinic in South Korea. Am J Health Syst Pharm. 2002;59(9):872–4.  
Reason for exclusion: Not a peer reviewed article -  narrative form only 
Culshaw M DS. Assessing the value of a discharge pharmacist. Pharm Manage. 1998;14(2):22–3.  
Reason for exclusion: Not a controlled study 
D’Achille KM SL Hill WT Jr. Pharmacist-managed patient assessment and medication refill clinic. Am J 
Hosp Pharm. 1978;35(1):66–70.  
Reason for exclusion: Not a controlled study - Pre- test post-test 
Entezari-Maleki T DS Hamishehkar H, Gholami K. A systematic review on comparing 2 common models 
for management of warfarin therapy; Pharmacist-led service versus usual medical care. Journal of Clinical 
Pharmacology. 2016;56(1):24–38.  
Reason for exclusion: Only includes studies in the Outpatient setting 
Erickson SH. Primary care by a pharmacist in an outpatient clinic. Am J Hosp Pharm. 1977;34(10):1086–
90.  
Reason for exclusion: Not hospital setting 
Feetam C NG. Pharmacist prescribing in mental health. Hosp Pharmacist - London. 2004;11(2):76–7.  
Reason for exclusion: Not a study - narrative only 
Fox ER BM Tyler LS. Pharmacy-administered IV to oral therapeutic interchange program: Development, 
implementation, and cost-assessment. Hosp Pharm. 2003;38(5):444–452+462.  
Reason for exclusion: Not considered pharmacist pre scribing 
Gray DR G-RS Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. 
Drug Intell Clin Pharm. 1985;19(7–8):575–80.  
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Haag JD DA Hoel RW, Armon JJ, Odell LJ, Dierkhising RA, Takahashi PY. Impact of Pharmacist-
Provided Medication Therapy Management on Healthcare Quality and Utilization in Recently Discharged 
Elderly Patients. Am Health Drug Benefits. 2016;9(5):259–68.  
Reason for exclusion: Not pharmacist prescribing - made recommendations only 
Hale AR. Doctor-Pharmacist Collaborative Prescribing in a Multidisciplinary Surgical Preadmission Clinic: 
Expanding the Role of the Preadmission Clinic Pharmacist. 2014;  
Reason for exclusion: Same information presented in  other 2 papers included for critical appraisal 
Hale A CI Stokes J, Aitken S, Clark F, Nissen L. Patient satisfaction from two studies of collaborative 
doctor - pharmacist prescribing in Australia. Health Expect. 2016;19(1):49–61.  
Reason for exclusion: Not true randomization - cont rol arm did not participate in satisfaction 
survey (no comparator) 
Hick HL, Deady PE, Wright DJ, Silcock J. The impact of the pharmacist on an elective general surgery 
pre-admission clinic. Pharmacy World and Science. 2001;23(2):65–9.  
Reason for exclusion: Not pharmacist prescribing - transcribing only 
Hwang S, Koleba T, Mabasa VH. Assessing the impact of an expanded scope of practice for pharmacists 
at a community hospital. The Canadian journal of hospital pharmacy. 2013;66(5).  
Reason for exclusion: Not a controlled study - retr ospective design 
Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical 
pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in jordan. Journal 
of Managed Care Pharmacy. 2012;18(7):516–26.  
Reason for exclusion: Not pharmacist prescribing 
Kirking DM, Svinte MK, Berardi RR, Cornish LA, Chaffee BW, Ryan ML. Evaluation of direct pharmacist 
intervention on conversion from parenteral to oral histamine H2-receptor antagonist therapy. DICP - 
Annals of Pharmacotherapy. 1991;25(1):80–4.  
Reason for exclusion: Not a controlled study - Pre- test post-test 
Kwan Y, Fernandes OA, Nagge JJ, Wong GG, Huh JH, Hurn DA, et al. Pharmacist Medication 
Assessments in a surgical preadmission clinic. Arch Intern Med. 2007;167:1034–40.  
Reason for exclusion: Pharmacist transcribing, not prescribing. Pharmacist generates post-op 
medication list. Surgeon then reviews list when pat ient is being discharged to indicate which 
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Lalonde L MJ Blais N, Montigny M, Ginsberg J, Fournier M, Berbiche D, Vanier MC, Blais L, Perreault S, 
Rodrigues I. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized 
controlled trial. Am Heart J. 2008;156(1):148–54.  
Reason for exclusion: Mixed hospital/community - co ntrol group were followed up at various 
places including hospital, physician's private offi ce or community centres 
Latter SB B, Smith A, Chapman ST M, Gerard K et al. Evaluation of nurse and pharmacist independent 
prescribing. 2010.  
Reason for exclusion: Not a study 
Latter S, Smith A, Blenkinsopp A, Nicholls P, Little P, Chapman S. Are nurse and pharmacist independent 
prescribers making clinically appropriate prescribing decisions? An analysis of consultations. Journal of 
health services research & policy. 2012;17(3):149–56.  
Reason for exclusion: Compared nurse prescribing to  pharmacist prescribing, mixed setting - 
hospital/community 
Lee Y, Schommer JC. Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital 
readmissions. Am J Health Syst Pharm. 1996;53:1580–3.  
Reason for exclusion: Not considered pharmacist pre scribing - did not specify that pharmacist 
prescribes warfarin doses 
Mamdani MM, Racine E, McCreadie S, et al. Clinical and economic effectiveness of an inpatient 
anticoagulation service. Pharmacotherapy. 1999;19(9):1064–74.  
Reason for exclusion: Observational Study  
McFadzean E, Isles C, Moffat J, Norrie J, Stewart D. Is there a role for a prescribing pharmacist in 
preventing prescribing errors in a medical admission unit? Pharmaceutical Journal. 2003;270(7255):896–
9.  
Reason for exclusion: Not a controlled study - Pre- test post-test. Not considered pharmacist 
prescribing – pharmacist charted medication history  for doctor to sign 
McGhan WF, Stimmel GL, Hall TG, Gilman TM. A comparison of pharmacists and physicians on the 
quality of prescribing for ambulatory hypertensive patients. Medical Care. 1983;21(4):435–44.  
Reason for exclusion: Not a controlled study - retr ospective design 
Mearns BM. Hypertension: Benefit of pharmacists prescribing antihypertensive medication. Nature 
Reviews Cardiology. 2015;12(8):443–443.  
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Menard PJ, Krishner BS, Koth DD, Pyka RS, Hill LR, Ventakaraman K. Management of the hypertensive 
patient by the pharmacist prescriber. Hosp Pharm. 1986;21:20–33.  
Reason for exclusion: Not a controlled study - Pre- test post-test 
Nelson LA, Cummings DM, Downs GE, Seaman JJ. Financial impact of a pharmacist-managed 
medication refill clinic. Military Medicine. 1984;149(5):254–6.  
Reason for exclusion: Not a controlled study - Pre- test post-test 
Parekh R Ghee, C. Evaluation of a pharmacist controlled anticoagulation clinic. Br J Pharm Prac. 
1987;370–81.  
Reason for exclusion: Not a controlled study - Pre- test post-test 
Patel-Naik B, Szeinbach SL, Seoane-Vazquez E, Snider MJ, Hevezi MS. Managing oral anticoagulation 
therapy by pharmacists in a specialty heart hospital. J Eval Clin Pract. 2010;16(1):192–5.  
Reason for exclusion: Not a controlled study - Pre- test post-test 
Rapoport A, Akbik H. Pharmacist-managed pain clinic at a Veterans Affairs medical center. American 
Journal of Health-System Pharmacy. 2004;61(13):1341–3.  
Reason for exclusion: Not a study - narrative only 
Rosen CE, Holmes CE. Pharmacist’s impact on chronic psychiatric outpatients in community mental 
health. Am J Hosp Pharm. 1978;35:704–8.  
Reason for exclusion: Not hospital setting, study c onducted at local community mental health 
centres 
Saokaew S, Permsuwan U, Chaiyakunapruk N, Nathisuwan S, Sukonthasarn A. Effectiveness of 
pharmacist-participated warfarin therapy management: A systematic review and meta-analysis. Journal of 
Thrombosis and Haemostasis. 2010;8(11):2418–27.  
Reason for exclusion: Does not specifically look at  studies in the hospital setting 
Schneider PJ, Larrimer JN, Visconti JA, Miller WA. Role effectiveness of a pharmacist in the maintenance 
of patients with hypertension and congestive heart failure. Contemp Pharm Pract. 1982;5(2):74–9.  
Reason for exclusion: Pharmacist made suggestions i n the study group. Doctor saw patient after 
pharmacist and made amendments as necessary. Not co nsidered pharmacist prescribing 
Scott J. Evaluation of the first pharmacist non medical prescriber in addiction treatment in Somerset: 
Report for Somerset DAAT. 2010.  
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Shalansky KF, Sunderji R. A simple warfarin dosing nomogram for orthopedic prophylaxis. Canadian 
Journal of Hospital Pharmacy. 2000;53(1):4–44.  
Reason for exclusion: Not a controlled study - Pre- test post-test 
Stimmel GL, McGhan WF, Wincor MZ, Deandrea DM. Comparison of pharmacist and physician 
prescribing for psychiatric inpatients. American Journal of Hospital Pharmacy. 1982;39(9):1483–6.  
Reason for exclusion: Study setting: Health mainten ance organization (HMO) mental health 
facility.  
Willey ML, Chagan L, Sisca TS, Chapple KJ, Callahan AK, Crain JL, et al. A pharmacist-managed 
anticoagulation clinic: six year assessment of patient outcomes. Am J Health Syst Pharm. 2003;60:1033–
7.  
Reason for exclusion: Not a controlled study - obse rvational, retrospective design 
Williams S, Younis N. Impact of a pharmacist prescriber in a university hospital multidisciplinary diabetic 
clinic. Pharmacy World & Science. 2007;29(3):299–301.  
Reason for exclusion: Not a controlled study - obse rvational, retrospective design 
Wong YM, Quek YN, Tay JC, Chadachan V, Lee HK. Efficacy and safety of a pharmacist-managed 
inpatient anticoagulation service for warfarin initiation and titration. Journal of Clinical Pharmacy and 
Therapeutics. 2011;36(5):585–91.  
Reason for exclusion: Not pharmacist prescribing - pharmacist recommended doses only 
You JHS, Cheng G, Chan TYK. Comparison of a clinical pharmacist–managed anticoagulation service 
with routine medical care: Impact on clinical outcomes and health care costs. Hong Kong Medical 
Journal. 2008;14:S23–7.  
Reason for exclusion: Same study as the one by Chan  2006 which is already included in the 
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APPENDIX III – JBI CRITICAL APPRAISAL CHECKLIST FOR  
RANDOMIZED CONTROLLED TRIALS 
Reviewer      Date       
Author      Year   Record Number   
 Yes No Unclear NA 
1. Was true randomization used for assignment of 
participants to treatment groups? □ □ □ □ 
2. Was allocation to treatment groups concealed? □ □ □ □ 
3. Were treatment groups similar at the baseline? □ □ □ □ 
4. Were participants blind to treatment assignment? □ □ □ □ 
5. Were those delivering treatment blind to treatment 
assignment?  □ □ □ □ 
6. Were outcomes assessors blind to treatment 
assignment? □ □ □ □ 
7. Were treatments groups treated identically other than 
the intervention of interest? □ □ □ □ 
8. Was follow-up complete, and if not, were strategies to 
address incomplete follow-up utilized? □ □ □ □ 
9. Were participants analysed in the groups to which they 
were randomized? □ □ □ □ 
10. Were outcomes measured in the same way for 
treatment groups? □ □ □ □ 
11. Were outcomes measured in a reliable way? □ □ □ □ 
12. Was appropriate statistical analysis used? □ □ □ □ 
13. Was the trial design appropriate, and any deviations 
from the standard RCT design (individual randomization, 
parallel groups) accounted for in the conduct and 
analysis of the trial? 
□ □ □ □ 
Overall appraisal:  Include  □ Exclude   □ Seek further info  □ 
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APPENDIX IV – JBI CRITICAL APPRAISAL CHECKLIST FOR 
QUASI EXPERIMENTAL STUDIES (NON RANDOMIZED 
EXPERIMENTAL STUDIES) 
Reviewer      Date       
Author      Year   Record Number        
 Yes No Unclear Not 
applicable 
1. Is it clear in the study what is the ‘cause’ and what is 
the ‘effect’ (i.e. there is no confusion about which 
variable comes first)? 
□ □ □ □ 
2. Were the participants included in any comparisons 
similar?  
□ □ □ □ 
3. Were the participants included in any comparisons 
receiving similar treatment/care, other than the 
exposure or intervention of interest? 
□ □ □ □ 
4. Was there a control group? □ □ □ □ 
5. Was there multiple measurements of the 
outcome/conditions both pre and post the 
intervention/exposure? 
□ □ □ □ 
6. Was follow-up complete, and if not, was follow-up 
adequately reported and strategies to deal with loss 
to follow-up employed? 
□ □ □ □ 
7. Were the outcomes of participants included in any 
comparisons measured in the same way?  
□ □ □ □ 
8. Were outcomes measured in a reliable way? □ □ □ □ 
9. Was appropriate statistical analysis used? □ □ □ □ 
Overall appraisal:  Include  □ Exclude   □ Seek further info  □ 
Comments (Including reason for exclusion) 
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APPENDIX V – SUMMARY OF INCLUDED STUDIES  






Outcome measures/Study results  Author conclusions and 
reviewer’s comments 
























(by protocol): Doctors 
initiated warfarin 
prescribing according to 
guideline and 
pharmacist prescribed 
warfarin according to 
guidelines from Day 4 
onwards 
 
N = 74 
 
Mean age:  
54 years (Range 17-74) 
 
Gender: 
Male: 36 (49%) 
Female: 38 (51%) 
Usual care:  
Doctors initiated and 
continued prescribing 
warfarin according to 
guidelines 
 
N = 64 
 
Mean age:  




Male: 34 (53%) 
Female: 30 (47%) 
Statistical methods: 
χ2 test , Kruskal-Wallis 
 
Percentage International Normalized Ratio (INR) (fr om 
Day 4 onwards): 
-  Within target range:  
Intervention: 58% 
Control: 18% 
p < 0.001 
-  Subtherapeutic (INR < 2.0):  
Intervention: 10% 
Control: 32% 
Significance not reported 
-  Supratherapeutic (INR > 6.0):  
Intervention: 1% 
Control: 5% 
Significance not reported 
 
 
Author’s conclusion:  
The pharmacist 
demonstrated significantly 
better (p = 0.001) INR 
control compared to junior 
doctors in terms of INR 
being in therapeutic range 
from Day 4 onwards 
 
Reviewer’s comments: 
Compared junior doctor 
prescribing to prescribing by 
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Outcome measures/Study results  Author conclusions and 
reviewer’s comments 





















with excess INR 
values where 
warfarin was not 






warfarin according to 
guidelines following 
initiation of prescription 
by doctors (by writing 
‘warfarin as per protocol’ 
on chart) 
 
N = 33 
 
Mean age:  




Usual care: Doctors 
prescribed warfarin as 
usual and had access 
to warfarin prescribing 
guidelines 
 
N = 33 
 
Ave age:  







Analysis of variance 
 
Adverse events - warfarin related complications: 
Intervention: 6% (2/33) – 2 strokes  
Control: 12% (4/33) – 1 stroke, 3 bleeds 
Significance not reported  
 
Percentage of patients with (according to guideline s): 
- Appropriate loading doses: 
Intervention: 100% (14/14) 
Control: 73% (11/15) 
Significance not reported;  
Fisher’s exact test: p = 0. 
- Appropriate maintenance doses following loading: 
Intervention: 100% (14/14) 
Control: 46% (7/15) 
F (1, 26) = 17.33, p < 0.001 
 
Percentage patients within target INR range:  
- Day 4 after loading: 
Intervention: 57% (8/14) 
Control: 46% (7/15) 
Significance not reported;  
Fisher’s exact test: p = 0.72 
- On discharge/transfer: 
Intervention: 68% (19/28) 
Control: 73% (22/30) 
Significance not reported;  
Fisher’s exact test: p = 0.77 
- At the outpatient clinic: 
Intervention: 61% (13/21) 
Control: 79% (19/24) 
Significance not reported;  
Fisher’s exact test: p = 0.32 
 
Percentage patients under- or over- anticoagulated (+/- 
0.2 INR units) at any point during treatment: 
Intervention: 67% (22/33) 
Control: 91% (30/33) 
F (1, 64) = 6.17, p = 0.016 
Author’s conclusion:  
Warfarin-dosing by 
pharmacists for inpatients 
had a beneficial effect on 




Compared three pharmacist 
prescribers with experience 
running an outpatient 
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enrolled in an 
anticoagulation 
clinic who were 
newly commenced 
on warfarin with an 
anticipated 
treatment duration 
of 3 months or more 







with warfarin for less 
than 3 months 
Dependent Prescribing 
(by protocol): One 
clinical pharmacist 
prescribed warfarin 
according to guidelines  
 
N = 68 
 
Mean age +/- SD:  
58 years +/- 14 
 
Gender: 
Male: 24 (35%) 
Female: 44 (65%) 
Usual care:  Doctor 
run anticoagulation 
clinic managed by 2 





N = 69 
 
Mean age +/- SD:  
60 years +/- 14 
 
Gender: 
Male: 38 (55%) 
Female: 31 (45%) 
Statistical methods: 
Unpaired student’s t-test, χ2 test, Fisher’s exact test, Mann-
Whitney test 
 




Intervention: 1 (1.6) 
Control: 2 (3.1) 
p = 1.00 
- Fatal: None in both groups 
Significance not reported 
 
Thromboembolic events : 
- Major: 
Intervention: 1 (1.6) 
Control: 1 (1.6) 
p =1.00 
- Fatal: None in both groups 
Significance not reported 
 
Patient time spent: 
- In therapeutic INR range: 
Intervention: 64% 
Control: 59% 
p < 0.001 
- In extended therapeutic range (+/- 0.2 INR units): 
Intervention: 78% 
Control: 76% 
p < 0.001 
 
Patient satisfaction survey  (PSQ-18) 
- Mean score: 
General satisfaction: 
Intervention: 4.0 +/- 0.5 
Control: 3.8 +/- 0.5 
p = 0.134 
Author’s conclusion:  
The pharmacist-managed 
anticoagulation service was 
more effective and less 
costly than the doctor-
managed service in 
achieving target 
anticoagulation control for 




All patients were Chinese.  
 
Study supported by the 
Health Care and Promotion 
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Outcome measures/Study results  Author conclusions and 
reviewer’s comments 



















amputation or stroke 
and who were 




less than 24 hours, 
patients received 
less than 24 hours 
of warfarin therapy 
Dependent Prescribing 
(by protocol): A single 
certified anticoagulation 
pharmacist prescribed 
warfarin according to 
guidelines to patients 
who were admitted to a 
single rehabilitation unit 
and referred to the 
warfarin dosing service  
 
N = 33 
 
Mean age (Range): 
72 years (47-88) 
 
Gender: 
Male: 6 (18%) 
Female: 27 (82%) 
Usual care:  Warfarin 
dosing by 
rehabilitation doctors 





N = 33 
 
Mean age (Range): 
71 years (34-96) 
 
Gender: 
Male: 8 (24%) 
Female: 25 (76%) 
Statistical methods: 
No statistical analysis performed 
 
Adverse events – warfarin related complications:  
- New diagnosis of DVT, PE or CVA, or death related to 
warfarin therapy: 
     - Deep Vein Thrombosis: None in both groups 
     - Pulmonary Embolism: 
       Intervention: 0 
      Control: 1 (2%)  
     - Cerebrovascular Accident: None in both groups 
     - Death: 
       Intervention: 0 
       Control: 1 (2%) 
 
- Hemorrhagic events: 
     - Minor:  
       Intervention: 1 (3%) 
       Control: 2 (6%) 
     - Major: 
       Intervention: 0 
       Control: 2 (6%) 
     - Life-threatening: None in both groups 
 
Percentage INRs: 
- Within target range: 
Intervention: 67.9% 
Control: 50.9% 
-  Subtherapeutic (INR < 2.0):  
Intervention: 22.7% 
Control: 33.2% 
-  Supratherapeutic (INR 3.01-3.99):  
Intervention: 9.1% 
Control: 12.8% 
-  Supratherapeutic (INR 4-6):  
Intervention: 0.3% 
Control: 2.1% 




Mean time to first therapeutic INR: 
Intervention: 2.8 days (Range 0-10) 
Control: 3 days (Range 0-14) 
Author’s co nclusion:  
The warfarin dosing service 
was safer and more effective 
than dosing provided by 
doctors. The pilot project for 
pharmacy anticoagulation 
service was deemed 
successful and could be 
expanded to all rehabilitation 
units within the institution 
 
Reviewer’s comments: 
The aim of this study was to 
implement and evaluate a 
warfarin dosing service for 
rehabilitation medicine. 
Patients in the control arm 
were managed by 
rehabilitation doctors and 
those in the intervention arm 
by a certified anticoagulation 
pharmacist. Patients in the 
concurrent control group 
were identified 
retrospectively and data 
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(by protocol): Seven 
pharmacists prescribed 
heparin and warfarin 
doses according to 
guidelines to patients 




(blinded) for study 
comparison 
 
N = 42 
 
Mean age (+/- SD): 
46 years +/- 16 
 
Gender: 
Male: 19 (45%) 
Female: 23 (55%) 
Usual care:   
One doctor prescribed 
heparin and warfarin 
doses. Pharmacist 
prescribed simulated 
doses (blinded) which 
was not administered.  
 
N = 39 
 
Mean age (+/- SD): 
52 years +/- 16 
 
Gender: 
Male: 16 (41%) 
Female: 23 (59%) 
Statistical methods: 
Unpaired student’s t-test, χ2 analysis with Yate’s correction 
 
Adverse events (Hemorrhagic events): 
- Minor:  
Intervention: 4 (10%) 
Control: 0 
- Major: 
None in both groups 
Significance not reported 
 
Time to reach therapeutic proconvertin and prothrom bin : 
Intervention: 5.7 +/- 1.4 days 
Control: 5.8 +/- 2.1 days 





Author’s conclusion:  
Certified pharmacist 
prescribers can adjust 
anticoagulant doses for 
inpatients according to a 




Both arms used a heparin 
protocol for dosage 
adjustment; warfarin dosage 
was adjusted using the 
proconvertin and 
prothrombin method. The 
doctor was new to the 
anticoagulation service while 
the pharmacists had a 
minimum of 6 months 
clinical experience treating 
patients with anticoagulants 
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Outcome measures/Study results  Author conclusions and 
reviewer’s comments 
Damaske and 


















and two internal 
medicine hospitalist 




Patients with a 
prosthetic heart 
valve, target INR > 
3, active bleeding, 
hematocrit < 25%, 
baseline INR > 1.3 





within 24 hours 
Dependent Prescribing 
(by protocol): Clinical 
pharmacists prescribed 
warfarin doses when the 
doctor wrote an order 
for “warfarin protocol per 
pharmacy”. Warfarin 
was dosed according to 
guidelines but deviation 
from guideline allowed 
according to clinical 
judgement.  
 







Usual care:  Doctors 
prescribed warfarin 
doses using warfarin 
guidelines 
 








No statistical analysis performed 
 
Adverse events – warfarin related complications: 
Minor hemorrhagic events: 
Intervention: 2 (7%) 
Control: 3 (14%) 
No other adverse events, minor or major, occurred in either 
group  
 
Patients receiving correct first dose of 5 mg:  
 Intervention: 29 (100%) 
Control: 15 (68%) 
Significance not reported 
Fisher’s exact test: p = 0.2085 
 
Percentage patients with supratherapeutic INR: 
Intervention: 5 (17%), INR range 3.3-7.4 
Control:  6 (27%), INR range 3.4-6.2 
Significance not reported 
 
Average time to therapeutic INR:  
Intervention: 6 days (Range 4-11) 
Control: 5.6 days (Range 4-11) 
 
Author’s conclusion:  
Pharmacist-managed 
inpatient warfarin protocol is 
an effective way of ensuring 
adherence to the latest 
evidence-based guidelines 
for warfarin administration. 
 
Reviewer’s comments: 
First warfarin dose of 5 mg 
was deemed appropriate but 
it is unclear if this was based 
on existing local guidelines 
in the control group as 
doctors did not appear to 
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Outcome measures/Study results  Author conclusions and 
reviewer’s comments 















elective surgery and 
attending 
preadmission clinic 
and able to provide 
written consent.  
 
Exclusion criteria: 
Patients under 18 
years of age, unable 






and urology patients 





prescribing:  Patients 
seen by a nurse, 
prescribing pharmacist, 
RMO and anesthetist. 
Patients were seen by 
the pharmacist before 
the RMO to enable 
counter-signature of 
prescriptions which was 
a site requirement. 
Pharmacist undertook 
all pharmacist duties as 
per usual care, as well 
as prescribing 








N = 194 
 
Mean Age: 




Male: 114 (59%) 
Female: 80 (41%) 
Usual care:  Patients 
seen by a nurse, 
pharmacist, resident 
medical officer (RMO) 
and anesthetist in no 
particular order. The 
RMO prescribed 
medications on the 
medication chart. 
 
N = 190 
 
Mean Age: 




Male: 110 (58%)  
Female: 80 (42%) 
Statistical methods: 
χ2 test, Fisher’s exact test, logistic regression 
 
Accuracy of medication charts: 
- Unintentional medication omissions (not prescribed): 
Intervention: Total 11/887 (1.2%), Regular medications:  3 
(0.3%), PRN medications: 8 (0.9%) 
Control: Total 383/1217 (31.5%), Regular medications: 248 
(20.4%), PRN medications: 135 (11.1%) 
p < 0.001 for regular medications 
 
- Prescribing errors: 
Intervention: 2 (0.2%) 
Control: 51 (6.3%) 
p < 0.001 
 
- Number of pharmacist prescriptions which required 
modification by a doctor: 
5 minor changes, 3 addition of analgesics out of the 
pharmacist’s prescribing scope, 2 changes resulted in 
inappropriate VTE prophylaxis  
 
Appropriate prescribing of chemical or mechanical 
venous thromboembolism prophylaxis: 
- In preadmission clinic:  
Intervention: 93.8% 
Control: 63.9% 
p < 0.001 
- On admission: 
Intervention: 93.1% 
Control: 89.5% 
p = 0.29 
Author’s conclusion:  
Medication charts in the 
intervention arm contained 
fewer clinically significant 
omissions and prescribing 
errors, when compared with 
controls. There was no 
difference in 
appropriateness of VTE 
prophylaxis on admission 
between the two groups.  
 
Reviewer’s comments: 
The pharmacist prescriber 
had a postgraduate diploma 
in clinical pharmacy, 3 years 
of experience in hospital 
pharmacy and had attended 
a prescribing course which 
was accredited in the UK. 
Clinical significance of 
omissions is reported in 
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Outcome measures/Study results  Author conclusions and 
reviewer’s comments 

















As in Hale et al (2013) 
 
N = 10 
 
Mean Age: 
58 years (Range 34-77) 
 
Gender: 
Male: 6 (60%)  
Female: 4 (40%) 
Usual care:   
As in Hale et al (2013) 
 
N = 9 
 
Mean Age: 








χ2 test, Fisher’s exact test 
 
Appropriateness of prescriptions: 
(According to a modified Medication Appropriateness Index; 
Outcomes were assessed by a panel consisting of a 
consultant anesthetist, a consultant hepatobiliary surgeon, a 
consultant clinical pharmacologist, a senior pharmacist, a 
senior nurse and a resident medical officer) 
 
Inappropriate prescriptions: 
Overall (combined assessment): 
Intervention: 13/266 (4.9%) 
Control: 32/294 (10.9%) 
Significance not reported; 
Fisher’s exact test: p = 0.0121 
Based on individual reviewer’s assessment: 
Only statistically significant for the pharmacist with no 
medications assessed as inappropriate in the intervention arm 
compared to 6/61 medications in the control arm (p = 0.029). 
 
Unintentional medication omissions (regular medications): 
Intervention: 1/55 (2%) 
Control: 25/89 (28%) 
p < 0.001 
 
Clinical significance of medication omissions: 
Intervention:  Only 1 reviewer thought the single occurrence of 
omission was significant 
Control: On average, 52% omissions rated to have potential to 
cause patent harm or ward inconvenience 
Author’s conclusion:  
Appropriateness of 
prescribing was similar 
between arms, Medication 
charts in the control arm 
contained slightly more 
omissions than the 
intervention arm, a number 
of which were rated by the 
panel members as having 




In this paper, 5% of the 
patient population from Hale 
et al (2013) were randomly 
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Outcome measures/Study results  Author conclusions and 
reviewer’s comments 











All adult patients 
with hypertension 
and diabetes seen 
at the medical follow 




due to absence of 
chronic illness, 
incomplete medical 
record, enrolled in 
another study, 
transferred to 
another health care 
facility, late entry 
into the study 
Collaborative 
prescribing: Pharmacist 
with 2 years of clinical 
training in general 
medicine managed 
patients, assisted by 
doctor of pharmacy 
candidates. All patient-
care assessments and 
plans made by the 
pharmacist were 
subsequently reviewed 
by doctor auditors to 
assure provision of 
adequate medical care 
to patients   
 






Male: 85 (24.4%) 
Female: 264 (75.6%) 
Usual care:  Clinical 
doctor (Assoc. Prof. of 
family practice) 
assisted by 4 
vocational nurses 
provided usual care. 
 






Male: 63 (22.5%) 
Female: 217 (77.5%) 
Statistical methods: 
χ2 analysis with Yate’s correction, z test, t-test, analysis of 
covariance   
 
Pre-test and post-test SBP, DBP, fasting BSLs: 
 
Mean Systolic Blood Pressure (mm Hg): 
- Pre-test: 
Intervention: 145 +/- 15 
Control: 143 +/- 14 
Not statistically significant 
- Post-test (between 24 to 29 months): 
Intervention: 147 +/- 18 
Control: 141 +/- 13 
p ≤ 0.001, t = 3.88 
 
Mean Diastolic Blood Pressure (mm Hg): 
- Pre-test: 
Intervention: 86 +/- 6 
Control: 86 +/- 6 
Not statistically significant 
- Post-test (between 24 to 29 months): 
Intervention: 84 +/- 6 
Control: 84 +/- 4 
Not statistically significant 
 
Mean fasting Blood Sugar Level (mg/dL): 
- Pre-test: 
Intervention: 192 +/- 46 
Control: 182 +/- 39 
p ≤ 0.05 
- Post-test (between 24 to 29 months): 
Intervention: 184 +/- 42 
Control: 189 +/- 49 
p = 0.058 
Author’s conclusion:  
This study provides 
additional evidence to justify 
safe and effective role of the 
clinical pharmacist in the 
post-diagnostic 
management of patients with 
diabetes mellitus and 
hypertension. 
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Outcome measures/Study results  Author conclusions and 
reviewer’s comments 











Adult patients with 
Type 2 diabetes 
seen in an 
ambulatory general 
medicine clinic, over 
18 years old, HbA1c 
> 8% which was 
obtained more than 
6 months before 
data acquisition 






care outside of 
Lahey Clinic 
Burlington campus, 
diagnosis of Type 1 
diabetes, HbA1c < 
8% within 6 months 
of randomization, 





management by an 
outside 
endocrinologist, 





practitioners with a 
minimum of 
postgraduate residency 
training with emphasis 
in ambulatory care and 
experience in directly 
caring for patients with 
chronic diseases 
managed the care of 
patients. Their duties 
included adjustment in 
therapy, lab testing or 
referral to other 
services, which required 
approval by the referring 
doctor before being 
implemented by the 
pharmacist.  
 
N = 72 
 
Mean age (+/- SD): 
62.7 years +/- 10.8 
 
Gender: 
Male: 49 (68%) 
Female: 23 (32%) 
Usual care:  Doctors 
provided usual care 
 
N = 92 
 
Mean age +/- SD: 
63.0 years  +/- 11.2 
 
Gender: 
Male: 51 (55%) 
Female: 41 (45%) 
Statistical methods:  
Unpaired t tests, Fisher’s exact tests 
 
Pre-test and post-test HbA1c, LDL cholesterol, SBP,  DBP: 
Mean HbA1c +/- SD (%): 
- Pre-test: 
Intervention: 9.5 +/- 1.1 
Control: 9.2 +/- 1.0 
p = 0.07 
- Post-test (12 months): 
Intervention: 7.7 +/- 1.3 
Control: 8.4 +/- 1.6 
p = 0.003 
 
Mean Low Density Lipoprotein +/- SD (mmol/L): 
- Pre-test: 
Intervention: 3.1 +/- 0.8 
Control: 3.0 +/- 0.9 
p = 0.227 
- Post-test (12 months): 
Intervention: 2.4 +/- 0.5 
Control: 2.7 +/- 0.9 
p = 0.01 
 
Mean Systolic Blood Pressure +/- SD (mm Hg): 
- Pre-test: 
Intervention: 142.5 +/- 15.2 
Control: 134.8 +/- 16.9 
p = 0.003 
- Post-test (12 months): 
Intervention: 132.5 +/- 16.3 
Control: 135.4 +/- 14 
p = 0.223 
 
Mean Diastolic Blood Pressure +/- SD (mm Hg): 
- Pre-test: 
Intervention: 79.4 +/- 9.9 
Control: 78.3+/- 10.4 
p = 0.493 
- Post-test (12 months): 
Intervention: 72.0 +/- 8.5 
Control: 77.6 +/- 8.4 
p = 0.001 
 
Patients reaching primary endpoints for HbA1c ( ≤7%) , 
LDL cholesterol ( ≤100 mg/dL), SBP ( ≤ 130 mm Hg), DBP ( ≤ 
80 mm Hg): 
No statistically significant differences between arms 
Author’ s conclusion:  
For all indices measured, 
this study demonstrated that 
collaborative diabetes 
management with a clinical 




This study received an 
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patients, no regular 
medications, unable 
to provide consent, 
medication charted 
during pre-operative 
clinic visit, admitted 
as day-only patient 
Supplementary 
Prescribing: Pharmacist 
interviewed patients on 
day of surgery and 
documented a regular 
medication list, which 
was also prescribed on 
the medication chart. 
Pharmacist prescribing 
was guided by protocols 
which advised which 
medications should be 
withheld and for how 
long depending on type 
of surgery 
 
N = 118 
 
Median age (IQR): 
64 years (47-75) 
 
Gender: 
Male: 60 (51%) 
Female: 58 (49%) 
Usual care:   
Patients had their 
medications charted 
immediately prior to 
surgery or 
postoperatively by a 
doctor in the normal 
timeframe. No clinical 
pharmacist 
consultations occurred 
prior to surgery 
 
N = 118 
 
Median age (IQR): 
65 years (54-75) 
 
Gender: 
Male: 58 (49%) 




Average number doses missed  inappropriately during  
inpatient stay: 
Intervention: 1.07 (CI 0.9-1.25) 
Control: 3.21 (CI 2.89-3.52) 
p = 0.002 
 
Average number medications charted at incorrect dos e 
(CI): 
Intervention: 0.02  (95% CI 0-0.04) 
Control: 0.48  (95% CI 0.35-0.61) 
p < 0.05 
 
Average number medications charted at incorrect 
frequency (CI): 
Intervention: 0.015  (CI 0-0.06) 
Control: 0.29  (CI 0.19-0.39) 
p < 0.05 
Author’s conclusion:  
Many patients miss doses of 
regular medication during 
their hospital stay and 
preoperative medication 
history taking and 
supplementary prescribing 




In the control group, 
patients’ regular medications 
were obtained post 
discharge by the trial 
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Patients treated with 
thrombolytic agents 
(e.g. streptokinase), 
patients who were 
treated with heparin 
for less than 24 
hours 
Dependent Prescribing 
(by protocol): Doctors 
wrote an order for 
“heparin per protocol” to 
initiate pharmacist 
prescribing. Doctors 
could also initiate 
prescribing before 
electing to have the 
patient managed by the 
pharmacist. Once 
initiated, pharmacists 
calculated the loading 
dose and initial infusion 
rate based on patient 
weight and current 
diagnosis. Following 
this, any changes were 
managed according to 
protocol.  
 
Phase I : 






Phase II : 





Usual care:  
Consultant doctors 
provided usual care – 
use of the heparin 
protocol was not 
mandatory 
 
Phase I : 






Phase II : 









Number of days of heparin therapy per patient  
(Mean +/- SD): 
-Phase I: 
 Intervention: 4.66 +/- 2.54 
Control: 5.43 +/- 2.29 
Not statistically significant 
-Phase II: 
Intervention: 4.39 +/- 2.09 
Control: 4.79 +/- 2.01 
Not statistically significant 
 
Time to reach therapeutic APTT  
(Mean +/- SD): 
-Phase I: 
 Intervention: 16.52 +/- 10.92 
Control: 46.5 hours +/- 34.13 
p < 0.001 
-Phase II: 
Intervention: 9.32 +/- 3.78 
Control: 31.64 +/- 32.74 
p < 0.001 
 
Author’s conclusion:  
When voluntarily prescribed 
by doctors, full-dose 
continuous intravenous 
heparin therapy initiated and 
monitored by clinical 
pharmacists improved the 





The aim of this study was to 
implement a new heparin 
protocol and compare doctor 
and pharmacist prescribing. 
The study was carried out in 
2 phases – the second 
phase was carried out 
following revision of the 
heparin protocol to a lower 
therapeutic APTT range 
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Adult inpatients on 2 
internal medicine 
and 2 cardiology 
wards who received 
at least one 















pharmacists who had 
several years of 
general-medicine based 
clinical practice 
experience or residency 
training, or both, were 
responsible for initial 
dose selection and daily 
dose adjustment after 
warfarin was initiated by 
the primary team. 
 
N = 250 
 
Mean age +/- SD: 
64.1 years +/- 15.6 
 
Gender: 
Male:  135 (54%) 
Female: 115 (46%) 
Usual care:   
Patients’ management 
of anticoagulation at 
discretion of the 
primary care team. 
The primary care team 
had access to a 
clinical pharmacist 




Service (PDAS)  
 
N = 250 
 
Mean age +/- SD: 
68 years +/- 14.9 
 
Gender: 
Male: 141 (56.4%) 
Female: 109 (43.6%) 
Statistical methods: 
Student’s t test, Mann-Whitney U test, χ2, Fishers exact test 
 
Adverse events – warfarin related complications (du ring 
hospitalization or within 30 days of discharge): 
- Major bleeding events (%): 
Intervention: 2 (0.8%) 
Control: 1 (0.4%) 
p = 0.563 
- No thromboembolic events in either group 
 
Number of episodes of INR > 5 during hospitalizatio n or 
within 30 days of discharge: 
Intervention: 24 (9.6%) 
Control: 37 (14.8%) 




Author’s conclusion:  
Implementation of a 
pharmacist directed 
anticoagulation service 
provides a net improvement 
in  quality of care for the 




It is unclear if the doctors or 
pharmacists had access to a 
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admitted to general 
medical units and 
emergency short-










written by doctor 
before pharmacist 
review or patient 
admitted to ESSU 





(at least 2 years of 
experience in hospital 
pharmacy and 6 months 
experience in general 
medicine and 
credentialed to 
prescribe) took a 
medication history, 
performed a venous 
thromboembolism risk 
assessment, and had a 
face to face discussion 
with the admitting doctor 
about current medical 
and medication-related 
problems, following 
which a medication 




and VTE prophylaxis 
were charted by the 
pharmacist on the 
inpatient chart. 
 






Male: 175 (42.9%) 
Female: 233 (57.1%) 
Usual care:   
Standard medication 
charting by doctors of 




performed by a 
pharmacist within 24 
hours of admission 
 






Male: 218 (46.1%) 
Female: 255 (53.9%) 
Statistical methods: 
χ2, Fishers exact test, Student’s t test, Wilcoxon rank-sum test 
 
Medication errors detected within 24 hours of admis sion 
(Number of patients with omitted/incorrect/unnecessary drug, 
incorrect dose/frequency/route): 
Intervention: 15/408 (3.7%) 
Control: 372/473 (78.7%) 
p < 0.001 
 
Severity of errors per patient:  
p < 0.01 
-Insignificant risk: 
Intervention: 10 (2.4%) 
Control: 103 (21.8%) 
-Low risk: 
Intervention: 0 
Control: 13 (2.7%) 
-Moderate risk: 
Intervention: 4 (1%) 
Control: 81 (17.1%) 
-High risk: 
Intervention: 1 (0.2%) 
Control: 150 (31.7%) 
-Extreme risk: 
Intervention: 0 
Control: 25 (5.3%) 
NNT to prevent a case of high risk or extreme error: 2.7 
patients 
 
Error type:  
p < 0.01 












Author’s conclusion:  
Partnering between doctors 
and pharmacists to jointly 
chart initial medications on 
admission significantly 
reduced inpatient medication 
errors (including errors of 
high and extreme risk) 
among general medical and 
emergency short-stay 
patients with complex 




Errors were identified by an 
independent pharmacist 
assessor who was not 
blinded to randomization. 
Errors were then reviewed 
and assigned a risk rating by 
a blinded independent 
expert panel comprising of a 
general doctor, an 
emergency doctor and a 
senior clinical pharmacist.  
Study was funded by the 
Department of Health and 
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therapy and BP > 











Secondary cause of 
hypertension, 
missed more than 3 
appointments in the 
last year, in 
hypertensive crisis, 
NYHA class III or IV 
heart failure, end 





condition that limited 
life expectancy to 1 
year 
Dependent Prescribing 
(by protocol): Patients 
scheduled  once a 
month at the 
hypertension clinic to 
see pharmacist who had 
prescribing authority to 
make appropriate drug 
therapy changes in both 
drug selection and 
dosage in accordance 
with the sixth report of 
the Joint National 
Committee on the 
Detection, Evaluation, 
and Treatment of High 
Blood Pressure  
 
N = 26 
 
Mean Age +/- SD: 
64 +/- 10.9 
 
Gender: 
Male: 26 (100%) 
 
Usual care:   
Patients received 
traditional pharmacy 
services but did not 





N = 27 
 
Mean Age +/- SD: 
65.5 years +/- 7.8 
 
Gender: 
Male: 27 (100%) 
 
Statistical methods:  
Paired t test, two-sample t test, Fishers exact test, Wilcoxon 
rank-sum test 
 
Pre-test and post-test SBP and DBP: 
Mean Systolic Blood Pressure +/- SD (mm Hg): 
- Pre-test: 
Intervention: 149.0 +/- 15.3 
Control: 152.8 +/- 14.3  
p = 0.252 
- Post-test (6 months): 
Intervention: 130.5 +/- 13.2 
Control: 148.4 +/- 21 
p = 0.0002 
 
Mean Diastolic Blood Pressure +/- SD (mm Hg): 
- Pre-test: 
Intervention: 89.8 +/- 10.9 
Control: 77.9 +/- 11.9 
p = 0.0012 
- Post-test (6 months): 
Intervention: 77.5 +/- 10.7 
Control: 80.4 +/- 11.4 
p = 0.259 
 
Patients achieving target Blood Pressure: 
(< 140/90 mm Hg or < 130/80 mm Hg in diabetics) 
Intervention: 21 (81%) 
Control: 8 (30%) 
p = 0.001 
 
Patient satisfaction survey: 
Number of patients who experience the following situation 
most of the time (Data for sometimes, very rarely and never 
not shown): 
“I am very satisfied with the pharmacy services that I receive” 
Intervention: 88% 
Control: 68% 
p = 0.098 
Author’s conclusion:  
Pharmaceutical care 
improves blood pressure 
control and results in more 
patients with hypertension 
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Adult patients with 
peripheral vascular 
disease attending a 
vascular outpatient 
clinic, provided 
consent, had a LDL 
cholesterol level of 




unable to provide 
consent, part of 
another compliance 
study, unwilling or 
not able to be 
followed up for a 6 








lipid lowering drugs 
Collaborative 
Prescribing: 
Patients reviewed by a 
pharmacist with 7 years 
clinical experience 
during four 6-weekly 
visits. At each visit 
patients were given 
lifestyle advice. Before 
starting on a statin, they 
were provided with 
information and if 
patients agreed, statin 
was prescribed at the 
following visit. A statin 
dose adjustment and 
monitoring algorithm 
was available as a guide 
if required.  
 
N = 8 
 
Mean Age +/- SD: 
73 years +/- 9.5 
 
Gender: 
Male: 5 (62.5%) 
Female: 3 (37.5%) 
Usual care:   
Patients were given 
dietary advice, a 
booklet on cholesterol 
management and their 
lipid levels measured 
at baseline and 6 
months.  
 
N = 6 
 
Mean Age +/- SD: 
79 years +/- 6.1 
 
Gender: 
Male: 3 (50%) 
Female: 3 (50%) 
Statistical methods:  
No statistical analysis - sample size  too small  
 
Pre-test and post-test LDL and total cholesterol: 
 












- Post-test (6 months): 
Intervention: 4.0 
Control: 5.1 
Author’s conclusion:  
A suitably trained hospital 
pharmacist can undertake 
extended roles with a 
prescribing element.  
 
Reviewer’s comments: 
The study failed to recruit 
the target of 31 patients in 
each arm due to difficulties 
with recruitment and follow-
up.  
All prescriptions written by 
the pharmacist were 
countersigned by a 




1 Evidence Based Medicine (EBM). BestBETs Best Evidence Topics, 2012. [Internet]. 
[Cited 7 Feb 2018] Available from: http://bestbets.org/ accessed February 7 2018. 
2 Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence 
based medicine: what it is and what it isn’t. BMJ 1996; 312:71. 
3 The STM Report: An overview of scientific and scholarly journal publishing. 4th Ed. 
March 2015. [Internet]. [Cited 7 Feb 2018] Available from: http://www.stm-
assoc.org/2015_02_20_STM_Report_2015.pdf accessed February 7 2018. 
4 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotsche PC, Ioannidis JPA, et al. The 
PRISMA statement for reporting systematic reviews and meta-analyses of studies 
that evaluate health care interventions: explanation and elaboration. PLOS Med. 
2009; 6(7): e1000097.  
5 Joanna Briggs Institute Reviewer’s Manual. Aromataris E, Munn Z (Editors). The 
Joanna Briggs Institute, 2017. [Internet]. [Cited 7 Feb 2018] Available from: 
https://reviewersmanual.joannabriggs.org/ accessed February 7 2018. 
6 Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Green S 
(Editors). The Cochrane Collaboration Version 5.1.0 (updated March 2011). 
[Internet]. [Cited 7 Feb 2018] Available from: http://handbook-5-1.cochrane.org/ 
accessed February 2 2018. 
7 Systematic Reviews: CRD’s guidance for undertaking reviews in health care. Centre 
for Reviews and Dissemination. Jan2009. [Internet]. [Cited 7 Feb 2018] Available 
from: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf accessed 
February 2 2018. 
8 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. 








P a g e  | 120 
 
9 Schunemann H, Brozek J, Oxman A, editors. GRADE Handbook for grading quality 
of evidence and strength of recommendation. [updated October 2013].The GRADE 
Working Group 2013; [internet]. [cited 2017 August 11]. Available from: 
http://gdt.guidelinedevelopment.org/app/handbook/handbook.html#h.ygojbnr1bi5y 
accessed August 9 2017.  
10 Heath Workforce Australia 2013. Health Professionals Prescribing Pathway (HPPP) 
Project – Final Report. [Internet]. [Cited 20 Apr 2015]. Available from: 
http://www.hwa.gov.au/sites/uploads/HPPP-Final-Report-November-2013.pdf 
accessed March 28 2015. break  
11 World Health Organization. Guide to Good Prescribing – A Practical Manual. 
[internet]. [cited 2018 March 11]. Available from: 
http://apps.who.int/medicinedocs/en/d/Jwhozip23e/5.4.html accessed March 11 
2018.        
12 Hoti K, Hughes J, Sunderland B. An expanded prescribing role for pharmacists - an 
Australian perspective. Australas Med J. 2011; 4(4): 236-42. 
13 Tonna AP, Stewart D, West B, McCaig D. Pharmacist prescribing in the UK - a 
literature review of current practice and research. J Clin Pharm Ther. 2007; 32(6): 
545-56. 
14 Bhanbhro S, Drennan VM, Grant R, Harris R. Assessing the contribution of 
prescribing in primary care by nurses and professionals allied to medicine: a 
systematic review of literature. BMC Health Serv Res. 2011; 11:330.  
15 Chambers K, Sharma R. Pharmacist prescribing – past present and future. Royal 
Pharmaceutical Society. [Internet]. [Cited 17 Jan 2018] Available from: 
http://blog.rpharms.com/uncategorized/2016/07/20/pharmacist-prescribing-past-








P a g e  | 121 
 
16 Nissen L, Kyle G, Stowasser DA, Lum E, Jones A, McLean C, et al. Non-Medical 
Prescribing. Australian Health Workforce Institute, Collaboration NHW-Par.2010. 
[Internet]. [Cited 20 Apr 2015]. Available from: 
http://www.ahwo.gov.au/documents/NHWT/Non%20Medical%20Prescribing%20Fi
nal%20Report.pdf accessed April 1 2015.  
17 Health & care professions council. Medicines and Prescribing. [internet]. [cited 
2018 March 11]. Available from: https://www.hcpc-
uk.org/aboutregistration/medicinesandprescribing/ accessed March 11 2018.        
18 NPS Medicinewise. How medicines are approved for use in Australia. [internet]. 
[cited 2018 March 11]. Available from: https://www.nps.org.au/medical-
info/consumer-info/how-medicines-are-approved-for-use-in-australia?c=medicine-
schedules-and-availability-c86a56a7 accessed March 11 2018.        
19 Emmerton L, Marriott J, Bessell T, Nissen L, Dean L. Pharmacists and prescribing 
rights: review of international developments. J Pharm Pharmaceut Sci. 2005; 8(2): 
217-25. 
20 Stewart, D. Pharmacist prescribing: A view from the UK. J Pharm Pract Res.2009; 
39(1): 7-10. 
21 Gielen SC, Dekker J, Francke AL, Mistiaen P, Kroezen M. The effects of nurse 
prescribing: A systematic review. Int J Nurs Stud. 2014; 51(7): 1048-61. 
22 Kroezen M, Dijk L, Groenewegen P, Francke A. Nurse prescribing of medicines in 
Western European and Anglo-Saxon countries: a systematic review of the 
literature. BMC Health Serv Res. 2011; 11(127): 1-42. 
23 Weeks G, George J, Maclure K, Stewart D. Non-medical prescribing versus 
medical prescribing for acute and chronic disease management in primary and 
secondary care. Cochrane Database Syst Rev. 2016; 11: CD011227. 
24 Kay OC, Brien JE. Pharmacist Prescribing: Review of the Literature. J Pharm Pract 
Res. 2004; 34(4): 300-304. 
25 Finley PR, Crismon ML, Rush AJ. Evaluating the Impact of Pharmacists in Mental 





P a g e  | 122 
 
26 Cooper RJ, Anderson C, Avery T, Bissell P, Guillaume L, Hutchinson A, et al. 
Nurse and pharmacist supplementary prescribing in the UK--a thematic review of 
the literature. Health Policy. 2008; 85(3): 277-92. 
27 Poh EW, McArthur A, Roughead L. The effects of pharmacist prescribing on patient 
outcomes in the hospital setting: a systematic review protocol. JBI Database 
System Rev Implement Rep. 2016; 13(12): 4-13. 
28 Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat 
Med. 2012; 31(25): 2973-2984. 
29 Dean B, Barber N, Schachter M. What is a prescribing error? Qual Health Care. 
2000; 9: 232-237. 
30 Lewis PJ, Dornan T, Taylor D, Tully DT, Wass V, Ashcroft DM. Prevalence, 
incidence and nature of prescribing errors in hospital inpatients: A systematic 
review. Drug Saf. 2009; 32(5): 379-389. 
31 Garfield S, Reynolds, M, Dermont L, Franklin BD. Measuring the severity of 
prescribing errors: A systematic review. Drug Saf. 2013; 36: 1151-1157.  
32 The National Coordinating Council for Medication Error Reporting and Prevention. 
Moving into the Second Decade: Developing Recommendations and Developing 
Tools. June 2010. [Internet]. [Cited 14 Feb 2018] Available from: 
http://www.nccmerp.org/sites/default/files/fifteen_year_report.pdf accessed 
February 14 2018. 
33 Alanazi MA, Tully MP, Lewis PJ. A systematic review of the prevalence and 
incidence of prescribing errors with high-risk medicines in hospitals. J Clin 
Pharmacy Ther. 2016; 41(3): 239-245. 
34 Velo G, Minuz P. Medication errors: prescribing faults and prescription errors. Br J 
Clin Pharmacol. 2009; 67(6): 624-628.  
35 Al-Abri R, Al-Balushi A. Patient satisfaction survey as a tool towards quality 
improvement. Oman Med J. 2014; 29(1): 3-7. 
36 The Joanna Briggs Institute. JBI SUMARI 2017. Available from: 





P a g e  | 123 
 
37 The Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal tools for 
use in JBI Systematic Reviews: Checklist for Randomized Controlled Trials, 
Adelaide, Australia: The Joanna Briggs Institute; 2016. [Cited 13 Mar 2017]. 
Available from: http://joannabriggs.org/research/critical-appraisal-tools.html 
accessed January 2 2017.   
38 The Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal tools for 
use in JBI Systematic Reviews: Checklist for Quasi-Experimental Studies (non-
randomized experimental studies), Adelaide, Australia: The Joanna Briggs 
Institute; 2016. [Cited 13 Mar 2017]. Available from: 
http://joannabriggs.org/research/critical-appraisal-tools.html accessed January 2 
2017. 
39 Hale AR, Coombes ID, Stokes J, McDougall D, Whitfield K, Maycock E, et al. 
Perioperative medication management: expanding the role of the preadmission 
clinic pharmacist in a single centre, randomised controlled trial of collaborative 
prescribing. BMJ Open 2013; 3(7): e003027.  
40 Hale A, Martin J, Coombes I, McDougall D, Coombes J, Nissen L. A pilot study to 
assess the appropriateness of prescribing from a collaborative pharmacist 
prescribing study in a surgical pre admission clinic. J Pharma Care Health Sys. 
2014; 1(3): 1-6. 
41 Chan FWH, Wong RSM, Lau WH, Chan TYK, Cheng G, You JHS. Management of 
Chinese patients on warfarin therapy in two models of anticoagulation service – a 
prospective randomized trial. Br J Clin Pharmacol. 2006; 62(5): 601-609.  
42 Chenella FC, Klotz TA, Gill MA, Kern JW, McGhan WF, Paulson YJ, et al. 
Comparison of physician and pharmacist management of anticoagulant therapy of 
inpatients. Am J Hosp Pharm. 1983; 40(10): 1642-5.  
43 Hawkins DW, Fiedler FP, Douglas HL, Eschbach RC. Evaluation of a clinical 
pharmacist in caring for hypertensive and diabetic patients. Am J Hosp 





P a g e  | 124 
 
44 Jacobs M, Sherry PS, Taylor LM, Amato M, Tataronis GR, Cushing G. Pharmacist 
assisted medication program enhancing the regulation of diabetes (PAMPERED) 
study. J Am Pharm Assoc. 2012; 52(5): 613-621. 
45 Marotti SB, Kerridge RK, Grimer MD. A randomized controlled trial of pharmacist 
medication histories and supplementary prescribing on medication errors in 
postoperative medications. Anaesth Intensive Care. 2011; 39(6): 1064-1070. 
46 Vivian EM. Improving blood pressure control in a pharmacist-managed 
hypertension clinic. Pharmacotherapy. 2002; 22(12): 1533-1540. 
47 Weeks GR, Fyfe R. Hospital pharmacist-led lipid clinic for surgical patients with 
peripheral vascular disease at a regional Australian hospital. J Pharm Pract Res. 
2012; 42(1): 17-21. 
48 Boddy C. Pharmacist involvement with warfarin dosing for inpatients. Pharm World 
Sci. 2001; 23(1): 31-35. 
49 Burns N. Evaluation of warfarin dosing by pharmacists for elderly medical in-
patients. Pharm World Sci. 2004; 26(4): 232-237. 
50 Damaske D, Baird RW. Development and implementation of a pharmacist-
managed inpatient warfarin protocol. Proc (Bayl Univ Med Cent). 2005; 18(4): 397-
400. 
51 Pawloski SJ, Kersh PL. Therapeutic heparin monitoring service in a small 
community hospital. Hosp Pharm. 1992; 27(8): 703-706, 723. 
52 Schillig J, Kaatz S, Hudson M, Krol GD, Szandzik EG, Kalus JS. Clinical and safety 
impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 
2011; 6(6): 322-328 
53 Tong EY, Roman C, Mitra B, Yip G, Gibbs G, Newnham H, et al. Partnered 
pharmacist charting on admission in the general medical and emergency short-stay 
unit – a cluster-randomised controlled trial in patients with complex medication 





P a g e  | 125 
 
54 Chau T, Rotbard M, King S, Li MM, Leong WA. Implementation and evaluation of a 
warfarin dosing service for rehabilitation medicine: Report from a pilot project. Can 
J Hosp Pharm. 2006; 59(3): 136-47. 
55 Joint National Committee on the Detection, Evaluation, and Treatment of High 
Blood Pressure, The Sixth Report of the Joint National Committee on prevention, 
detection, evaluation, and treatment of high blood pressure. National Institutes of 
Health – National heart, lung, and blood institute. 1997 [cited 15 Mar 2017]. 
Available from: https://www.nhlbi.nih.gov/files/docs/guidelines/jnc6_archive.pdf 
accessed  5 Apr 2017.  
56 Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow up 
measurements. BMJ 2001; 323(7321): 1123-1124. 
57 Latter S, Maben J, Myall M, Young A. Evaluating the clinical appropriateness of 
nurses’ prescribing practice: method development and findings from an expert 
panel analysis. Qual Safe Health Care. 2007; 16(6): 415-421.  
58 Society of Hospital Pharmacists of Australia. Standards of Practice for clinical 
pharmacy services: Documenting clinical activities 2016; [internet]. [cited 2017 July 
3]. Available from: https://www.shpa.org.au/resources/standards-of-practice-for-
clinical-pharmacy-services accessed July 3 2017. 
59 Coombes ID, Stowasser DA, Coombes JA, Mitchell C. Why do interns make 
prescribing errors? A qualitative study. MJA. 2008; 188(2): 89-94.  
60 Dean B, Schachter M, Vincent C, Barber N. Causes of prescribing errors in hospital 
inpatients: a prospective study. Lancet. 2002; 359(9315): 1373-1378. 
61 Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient 
medical care. Arch Int Med. 2006; 166(9): 955-964.  
62 Rosenthal M, Hall KW, Bussieres JF, Tsuyuki RT. Professional culture and 
personality traits of hospital pharmacists across Canada: A fundamental first step 






P a g e  | 126 
 
63 Hall J, Rosenthal M, Family H, Sutton J, Hall K, Tsuyuki R. Personality traits of 
hospital pharmacists: Toward a better understanding of factors influencing 
pharmacy practice change. Can J Hosp Pharm. 2013; 66(5): 289-295. 
64 Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol. 2005; 
59(5): 491-494.  
65 Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the 
prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the 
context of expectations from prospective epidemiological studies. BMJ. 2009; 338: 
b1665.  
66 Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure 
reduction: a meta-analysis. Lancet. 2001; 358(9290): 1305-1315 
67 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug 
treatment in older persons with isolated systolic hypertension: Final results of the 
Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265(24): 3255-
3264. 
68 The Diabetes Control and Complications Trial Research Group. The effect of 
intensive treatment of diabetes on the development and progression of long-term 
complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 
977-986. 
69 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control 
with sulphonylureas or insulin compared with conventional treatment and risk of 
complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998; 
352(9131):837–853. 
70 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of 
macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). Br 
Med J. 1998; 317(7160):703–713. 
71 UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in 
reducing risk of macrovascular and microvascular complications in type 2 diabetes 





P a g e  | 127 
 
72 Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, 
et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. 
Diabetologia. 2009; 52(11): 2288–2298. 
73 Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. 
Effect of intensive control of glucose on cardiovascular outcomes and death in 
patients with diabetes mellitus: a meta-analysis of randomised controlled trials. 
Lancet. 2009; 373(9677): 1765–1772. 
74 Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, 
Kassai B, et al. Effect of intensive glucose lowering treatment on all cause 
mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-
analysis of randomised controlled trials. BMJ. 2011; 343: d4169.  
75 Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more 
intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 
participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670-1681. 
76 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 
high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 
360(9326):7-22.  
77 Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et 
al. Primary prevention of cardiovascular disease with atorvastatin in type 2 
diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre 
randomised placebo-controlled trial. Lancet. 2004; 364(9435):685-96.  
78 The Task Force for the management of dyslipiademias of the European Society of 
Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS 
Guidelines for the management of dyslipidaemias. Eur Heart J. 2011; 32: 1769-
1818. [internet]. [cited 2017 July 31].Available from: 
https://www.escardio.org/static_file/Escardio/Guidelines/publications/DYSLIPguidel
ines-dyslipidemias-FT.pdf accessed July 31 2017. 
79 Singh S, Loke YK. Drug safety assessment in clinical trials: methodological 





P a g e  | 128 
 
80 Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically 
significant differences in adverse event rates in randomized controlled trials. J Clin 
Epidemiol. 2009; 62(6): 609-616. 
81 Garcia P, Ruiz W, Munarriz CL. Warfarin nomograms for venous 
thromboembolism. Cochrane Database Syst Rev. 2016; 1: CD007699.   
82 Mahtani KR, Heneghan CJ, Nunan D, Bankhead C, Keeling C, Ward AM, et al. 
Optimal loading dose of warfarin for the initiation of oral anticoagulation. Cochrane 
Database Syst Rev. 2012; 12: CD008685. 10.1002/14651858.CD008685.pub2   
83 Schulman S, Beyth RJ, Keasron C, Levine MN. Hemorrhagic complications of 
anticoagulant and thrombolytic treatment. American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(Suppl 
6): 257S-298S. 
84 Gallus AS, Baker RI, Chong BH, Ockelford PA. Consensus guidelines for warfarin 
therapy: Recommendations from the Australasian Society of Thrombosis and 
Haemostasis. MJA. 2000; 172(12): 600-605. 
85 White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of 
outcomes among patients randomized to warfarin therapy according to 
anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007; 
167(3): 239-245. 
86 Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective 
intensity of prophylactic anticoagulation for patients with non-rheumatic atrial 
fibrillation. NEJM. 1996; 335(8): 540-546. 
87 Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor 
anticoagulation quality in the first 3 months after unprovoked venous 
thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost. 







P a g e  | 129 
 
88 Centers for Disease Control and Prevention, National Center for Chronic Disease 
Prevention and Health Promotion. A program guide for public health: Partnering 
with the pharmacist in the prevention and control of chronic diseases 2012; 
[internet]. [cited 2017 May 31].Available from: 
http://pubs.lib.umn.edu/cgi/viewcontent.cgi?article=1216&context=innovations 
accessed May 31 2017.  
89 Carter B. Evolution of clinical pharmacy in the USA and future directions for patient 
care. Drugs and Aging. 2016; 33(3): 169-177. 
90 Abramowitz PW. The evolution and metamorphosis of the pharmacy practice 
model. Am J Health-Syst Pharm. 2009; 66(16): 1437-1446. 
91 McCann LM, Haughey SL, Parsons C, Lloyd F, Crealey G, Gromley GJ, et al. A 
patient perspective of pharmacist prescribing: ‘crossing the speacialisms-crossing 
the illnessness’. Health Expect. 2015; 18(1): 58-68. 
92 Hoti K, Hughes J, Sunderland B. Pharmacy client’s attitudes on expanded 
pharmacist prescribing and the role of agency theory on involved stakeholders. Int 
J Pharm Pract. 2011; 19(1): 5-12. 
93 Child D, Cantrill JA. Hospital doctors’ perceived barriers to pharmacist prescribing. 
Int J Pharm Pract. 1999; 7(4): 230-237. 
94 Sciberras J, Said E, Cordina M. Perceptions of physicians and pharmacists on 
hospital physician-pharmacist collaboration: A qualitative insight. Int J Clin Pharm. 
2013; 35(5):859 
95 Stewart DC, George J, Bond CM, Diack HL, McCaig DJ, Cunningham S. Views of 
pharmacist prescribers, doctors and patients on pharmacist prescribing 
implementation. Int J Pharm Pract. 2009; 17(2): 89-94. 
96 Hoti K, Sunderland B, Hughes J, Parsons R. An evaluation of Australian 






P a g e  | 130 
 
97 McIntosh T, Munro K, Stewart D, McLay J. What do newly qualified pharmacists in 
Britain think about possible future roles as pharmacist prescribers? Int J Pharm 
Pract. 2010; 18(1): 27-28. 
98 Alberta College of Pharmacists. 2007.Health Professions Act Standards for 
Pharmacist Practice. [internet]. [cited 2018February 23]. Available from: 
https://pharmacists.ab.ca/sites/default/files/StandardsOfPractice_May2014.pdf 
accessed February 23 2018. 
99 Yuksel N,Eberhart G, Bungard TJ. Prescribing by pharmacists in Alberta. Am J 
Health-Syst Pharm. 2008; 65: 2126-2132. 
100 Zolezzi M. Pharmacist Prescribing: The Alberta Experience. [internet]. [cited 2018 
February 23].Available from: 
http://www.qu.edu.qa/pharmacy/research/presentation_docs_2014/FRS-
Rx_Prescribing-MZ-Nov14.pdf accessed February 23 2018. 
101 Pharmacist Prescribing Task Force. Prescribing by Pharmacists: Information 
Paper (2009). Can J Hosp Pharm. 2009; 63(3): 267-274. 
102 Law MR, Ma T, Fisher J, Sketris I. Independent pharmacist prescribing in Canada. 
Can Pharm J (Ott). 2012; 145(1): 17-23. 
103 Vickers AJ. The use of percentage change from baseline as an outcome in a 
controlled trial is statistically inefficient: a simulation study. BMC Med Res 
Methodol. 2001; 1:6 
104 World Health Organization. Hospitals; [internet]. [cited 2017 August 8]. Available 
from: http://www.who.int/hospitals/en/ accessed August 8 2017.        
105 The Joanna Briggs Institute Levels of Evidence and Grades of Recommendation 
Working Party. Supporting document for the Joanna Briggs Institute levels of 
evidence and grades of recommendation. Adelaide, Australia: The Joanna Briggs 
Institute; 2016. [Cited 5 Sept 2017]. Available from: www.joannabriggs.org/jbi-
approach.html#tabbed-nav=Grades-of-Recommendation accessed September 3 
2017.  
 
